influenza
acut
respiratori
viral
diseas
major
global
public
health
import
lower
respiratori
tract
infect
estim
caus
million
death
year
rang
million
approxim
caus
respiratori
virus
global
burden
diseas
collabor
emerg
high
morbid
virus
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
middl
east
respiratori
syndrom
corona
viru
merscov
influenza
well
discoveri
novel
viral
pathogen
human
metapneumoviru
human
bocaviru
highlight
import
intern
collabor
respiratori
viru
research
prevent
control
intern
societi
influenza
respiratori
virus
diseas
isirv
independ
intern
scientif
profession
societi
promot
prevent
detect
treatment
control
influenza
respiratori
viru
diseas
antivir
group
special
interest
group
isirv
isirvavg
specif
object
promot
understand
develop
antivir
respiratori
virus
collat
provid
date
inform
emerg
antivir
resist
establish
therapeut
also
aim
provid
inform
evalu
resist
new
therapi
develop
commun
advanc
preclin
clinic
develop
potent
novel
antivir
five
previou
confer
organ
isirvavg
isirvavg
held
confer
rockvil
md
novemb
threeday
program
focus
therapeut
toward
influenza
respiratori
syncyti
viru
rsv
respiratori
virus
topic
includ
ongo
recent
complet
clinic
trial
new
preclin
develop
therapeut
vaccin
regulatori
consider
studi
design
issu
aim
http
receiv
march
accept
april
confer
report
summar
present
given
meet
robert
johnson
barda
washington
dc
usa
biomed
advanc
research
develop
author
barda
partner
invest
divers
portfolio
research
compani
foster
innov
bolster
america
prepared
bioterror
threat
partnership
result
us
food
drug
administr
fda
approv
licens
clearanc
uniqu
product
barda
plan
advanc
respiratori
viru
therapeut
focus
three
topic
improv
diagnost
test
pursu
hostdirect
therapeut
improv
identif
treatment
sepsi
outbreak
faster
identif
faster
robust
respons
barda
support
work
improv
diagnost
goal
recogn
ill
symptom
develop
may
includ
wearabl
diagnost
biosensor
high
mortal
associ
human
infect
novel
coronavirus
merscov
sarscov
avian
influenza
strain
influenza
rais
question
possibl
role
dysregul
immun
respons
call
cytokin
storm
pathogenesi
sever
respiratori
diseas
patient
may
respond
typic
antipathogen
therapeut
eg
antivir
barda
pursu
therapeut
target
host
order
modifi
immunehost
respons
work
need
done
identifi
host
target
develop
therapeut
toward
dysregul
immun
respons
field
also
need
better
diagnost
guid
treatment
oversuppress
immun
respons
danger
overstimul
sepsi
one
urgent
costli
system
health
threat
common
pathway
mortal
associ
novel
pathogen
current
approach
develop
better
diagnost
identifi
treat
sepsi
earli
understand
immun
profil
activ
versu
suppress
diseas
barda
divis
research
innov
ventur
drive
establish
uniqu
publicpriv
partnership
could
acceler
therapeut
develop
identif
treatment
sepsi
threeprong
approach
diagnost
host
target
better
treatment
sepsi
barda
hope
decreas
risk
emerg
respiratori
virus
futur
lastli
dr
johnson
note
candid
therapeut
rsv
coronaviru
influenza
make
advanc
drug
develop
pivot
trial
lack
interest
pharmaceut
industri
yet
despit
cost
guarante
success
commerci
market
perspect
barda
view
develop
landscap
valley
deathadvanc
develop
valley
candid
look
promis
earli
studi
fail
pivot
studi
sustain
valley
candid
success
pivot
studi
fail
find
commerci
success
barda
histor
seen
role
mitig
risk
advanc
develop
howev
vest
parti
need
come
togeth
find
way
mitig
risk
sustain
stefani
vogel
univers
maryland
baltimor
md
usa
induct
acut
lung
injuri
caus
infect
occur
due
cytokin
storm
result
activ
inflammatori
respons
tolllik
receptor
pattern
recognit
receptor
prototyp
pathogenassoci
molecular
pattern
pamp
gramneg
bacteria
endotoxin
lipopolysaccharid
lp
implic
patholog
associ
infect
well
tissu
damag
caus
noninfecti
insult
signal
pathway
activ
lp
bind
initi
transfer
lp
noncoval
associ
coreceptor
lp
bind
lead
dimer
activ
vogel
laboratori
previous
show
mice
highli
resist
infect
mouseadapt
influenza
strain
shirey
et
al
provid
rational
block
signal
might
protect
influenza
infect
eritoran
structur
analog
lp
function
antagonist
bind
therebi
prevent
interact
lp
eritoran
demonstr
therapeut
benefit
context
protect
acut
lung
injuri
experiment
murin
cotton
rat
model
influenza
infect
administr
eritoran
daili
consecut
day
wildtyp
mice
start
day
infect
result
highli
signific
protect
lethal
improv
lung
patholog
moreov
signific
degre
surviv
observ
even
eritoran
administ
mice
start
late
day
postinfect
protect
influenza
infect
confirm
use
antagonist
includ
antibodi
cellperm
decoy
peptid
structur
analog
antagonist
small
molecul
antagonist
perrincocon
et
al
piao
et
al
eritoran
also
protect
cotton
rat
sigmodon
hispidu
infect
nonadapt
human
influenza
b
strain
sinc
influenza
known
express
pamp
hypothes
damageassoci
molecular
pattern
damp
elicit
infect
patel
et
al
infect
mice
cotton
rat
influenza
caus
releas
hostderiv
protein
shown
agonist
releas
die
cell
administr
eritoran
block
releas
blunt
influenzainduc
cytokin
induct
turn
result
improv
lung
function
revers
edema
reduc
viral
titer
moreov
administr
small
molecul
antagonist
provid
degre
protect
mice
eritoran
develop
secondari
bacteri
infect
context
infect
influenza
associ
higher
rate
morbid
mortal
particularli
pandem
data
present
show
signific
diseas
enhanc
mice
infect
initi
either
nonleth
lethal
dose
day
prior
superinfect
dose
pneumonia
kill
mockinfect
mice
target
host
immun
respons
use
eritoran
infect
prior
pneumonia
infect
larg
protect
enhanc
secondari
bacteri
infect
collect
data
demonstr
util
target
prevent
secondari
bacteri
infect
influenza
infect
andr
pizzorno
centr
intern
de
recherch
en
infectiologi
ciriteam
virpath
signia
therapeut
lyon
franc
therapeut
approach
treatment
influenza
outlin
involv
repurpos
drug
target
host
rational
target
host
rather
viru
host
less
like
develop
resist
therapeut
furthermor
virus
util
common
host
molecular
pathway
number
differ
virus
could
potenti
target
singl
therapeut
util
therapeut
alreadi
approv
complet
phase
clinic
trial
initi
indic
would
reduc
regulatori
burden
lower
develop
cost
clinic
gene
express
signatur
data
obtain
hospit
influenzaposit
patient
use
screen
potenti
drug
candid
infect
viru
modifi
cellular
express
creat
environ
facilit
translat
replic
viru
goal
find
drug
revers
process
creat
environ
within
host
unfavor
viru
first
step
gener
transcriptom
signatur
infect
use
sampl
obtain
cohort
hospit
patient
confirm
influenza
infect
baselin
sampl
month
later
transcriptom
signatur
compos
deregul
gene
pizzorno
et
al
influenza
viru
infect
signatur
screen
connectivitymap
databas
broad
institut
mit
connectivitymap
harbor
transcriptom
profil
differ
cell
line
treat
small
molecul
candid
drug
includ
neg
correl
along
addit
screen
consid
criteria
toxic
deliveri
method
yield
candid
molecul
underw
test
includ
minim
impact
cell
viabil
demonstr
abil
reduc
viral
titer
candid
fit
criteria
diltiazem
licens
calcium
channel
blocker
use
treatment
hypertens
identifi
candid
screen
confirmatori
vitro
vivo
test
use
valid
approach
pizzorno
et
al
pretreat
mice
diltiazem
h
prior
infect
shown
protect
result
reduc
peak
viral
titer
similarli
treatment
h
post
infect
provid
complet
protect
compar
control
group
high
mortal
lethal
model
influenza
infect
establish
mice
treatment
oseltamivir
diltiazem
success
rescu
mice
respect
halfdos
treatment
diltiazem
mgkg
rescu
mice
addit
studi
use
reconstitut
human
epitheli
cell
model
undertaken
gain
understand
mechan
action
impact
epitheli
cell
integr
diltiazem
current
evalu
combin
oseltamivir
patient
sever
influenza
clinicaltrialsgov
identifi
kevin
harrod
univers
alabama
birmingham
al
usa
treatment
option
limit
patient
diagnos
influenza
outsid
window
effect
treatment
use
antivir
lung
injuri
inflamm
primari
driver
sever
diseas
influenza
infect
also
set
condit
secondari
infect
new
focu
treatment
option
acut
lung
injuri
occur
result
pneumonia
driven
number
mediat
includ
innat
immun
cell
macrophag
matrix
metalloproteinas
mmp
associ
lung
develop
diseas
chronic
obstruct
pulmonari
diseas
copd
role
remodel
digest
collagen
mmp
gener
short
tripeptid
pgp
acetyl
serv
matrikin
extracellular
matrixderiv
peptid
regul
cell
activ
bind
receptor
caus
neutrophil
enter
lung
gaggar
et
al
digest
extracellular
matrix
remodel
occur
lung
transmigr
immun
cell
interstiti
space
air
space
import
drive
biolog
number
infect
preliminari
work
use
sampl
taken
cohort
studi
brigham
women
hospit
show
patient
admit
intens
care
unit
icu
enrol
pneumonia
po
less
mmhg
requir
supplement
elev
level
even
pronounc
patient
season
influenza
viru
also
shown
occur
mice
well
relat
serendipit
observ
demonstr
inhibit
protect
mous
model
influenza
exacerb
copd
observ
provid
impetu
identifi
candid
therapeut
target
use
potenti
treatment
option
vitro
test
carri
use
human
bronchial
epitheli
cell
isol
human
lung
tissu
obtain
organ
tissu
donat
program
intern
institut
advanc
medicin
gaggar
et
al
cell
grown
monolay
differenti
airliquid
interfac
recapitul
airway
epithelium
lung
dish
approach
test
inhibitor
candid
drug
target
develop
previous
treatment
copd
identifi
candid
repurpos
addit
number
antibiot
doxycyclin
mmp
inhibitor
also
show
reduc
viral
load
test
influenza
infect
mice
lower
neutrophil
macrophag
count
lung
lavag
reduc
lung
type
interferon
level
rojasquintero
et
al
addit
lung
epitheli
cell
lower
viral
titer
wt
cell
vitro
provid
foundat
identifi
addit
therapeut
target
antivir
antiinflammatori
effect
deborah
fuller
univers
washington
seattl
wa
usa
minibind
small
protein
comput
design
de
novo
develop
altern
platform
monoclon
antibodi
minibind
significantli
smaller
antibodi
design
higher
affin
target
epitop
interact
fc
receptor
conserv
influenza
ha
stem
region
necessari
receptor
attach
fusion
use
test
case
compar
minibind
tradit
antibodi
format
physiochem
properti
minibind
fleishman
et
al
manufactur
chevali
et
al
significantli
improv
recent
year
minibind
small
protein
amino
acid
bind
high
affin
improv
physiochem
properti
stabl
temperatur
vivo
studi
shown
protect
confer
minibind
independ
presenc
fc
contrast
monoclon
antibodi
bind
region
hemagglutinin
ha
shown
protect
fcmediat
minibind
administ
intranas
compar
efficaci
lower
dose
mgkg
minibind
molar
equival
mgkg
monoclon
antibodi
mice
furthermor
mice
challeng
influenza
singl
dose
minibind
gave
protect
initi
day
postinfect
repeat
dose
mice
use
show
low
immunogen
minibind
retain
protect
afterward
minibind
also
test
ferret
biodistribut
compar
intranas
inhal
rout
administr
h
deliveri
observ
differ
distribut
minibind
protein
anim
intranas
deliveri
minibind
present
lung
wherea
anim
given
inhal
deliveri
minibind
detect
throughout
trachea
lung
subsequ
ferret
challeng
aerosol
influenza
viru
minibind
administ
day
later
ferret
sacrif
day
detect
diseas
ferret
administ
minibind
current
minibind
target
group
virus
develop
preclin
character
broad
spectrum
potent
influenza
inhibitor
potenti
tripl
rout
oral
inhal
intraven
treatment
sam
lee
cocryst
pharma
inc
bothel
wa
usa
influenza
virus
replic
transcrib
genom
nuclei
infect
cell
via
trimer
viral
rna
polymeras
complex
polymeras
complex
compos
protein
subunit
pa
viral
replic
sever
new
class
polymeras
inhibitor
clinic
develop
target
subunit
includ
baloxavir
pa
favipiravir
pimodivir
new
inhibitor
discov
optim
use
structurebas
design
discoveri
vitro
character
preclin
data
yet
describ
seven
differ
influenza
domain
drugresist
variant
purifi
protein
crystal
high
resolut
xray
crystal
cocryst
reveal
inhibitor
occupi
gtp
bind
site
influenza
capbind
domain
interact
side
chain
highli
conserv
residu
glu
ly
furthermor
site
bind
highli
conserv
across
multipl
influenza
structur
vitro
antivir
drug
resist
select
studi
perform
pimodivir
firstinclass
subunit
inhibitor
clinic
develop
janssen
preliminari
data
sever
viral
variant
isol
reduc
antivir
activ
includ
drugresist
variant
confirm
mutat
restrict
gene
exhibit
broad
potent
antivir
activ
ic
valu
low
nanomolar
rang
nm
panel
season
pandem
influenza
strain
use
vitro
cytopath
effect
inhibit
assay
novel
formul
vehicl
three
rout
administr
oral
inhal
intraven
iv
develop
studi
mous
model
determin
pharmacokinet
pk
toxic
paramet
preclin
pk
safeti
profil
report
favor
rout
administr
phase
clinic
studi
set
commenc
later
determin
cristian
garcia
oswaldo
cruz
rio
de
janeiro
brazil
influenza
virus
caus
sever
infect
correl
intens
inflammatori
respons
character
secret
cytokin
influx
neutrophil
lung
damag
lead
death
neutrophil
activ
migrat
orchestr
differ
stimuli
like
platelet
activ
factor
paf
receptor
pafr
chemokin
mice
receptor
anaphylatoxin
other
aim
investig
test
potenti
pharmacolog
strategi
modul
host
inflammatori
respons
use
compound
differ
target
involv
neutrophil
activ
migrat
abil
improv
diseas
outcom
murin
influenza
infect
model
key
measur
report
studi
includ
assess
neutrophil
cell
count
balf
lung
infect
mice
viral
bacteri
load
histopatholog
score
lung
weight
loss
lethal
rate
first
target
pafr
pafr
antagonist
pca
tocri
bioscienc
co
given
oral
gavag
twice
day
day
day
infect
reduc
weight
loss
protect
mice
lethal
influenza
infect
improv
surviv
percent
day
pca
reduc
neutrophil
transmigr
airway
consequ
lung
patholog
day
infect
second
target
tick
saliva
deriv
protein
block
cleavag
omcl
given
intraperiton
day
day
omcl
abl
reduc
level
reduc
neutrophil
transmigr
airway
releas
neutrophil
extracellular
trap
consequ
lung
patholog
influenza
infect
third
target
antagonist
r
given
oral
gavag
twice
day
day
day
reduc
weight
loss
lung
damag
day
infect
treatment
influenza
infect
report
reduc
neutrophil
transmigr
airway
consequ
lung
patholog
influenza
infect
addit
given
day
day
influenza
infect
protect
mice
secondari
day
influenza
streptococcu
pneumonia
morbid
reduct
neutrophil
infiltr
lung
bacteremia
mice
fourth
approach
use
steroid
influenza
infect
examin
corticosteroid
dexamethason
given
alon
combin
suboptim
dose
oseltamivir
start
day
day
day
infect
reduc
lethal
observ
dexamethason
given
therapeut
initi
day
postinfect
given
prophylact
day
case
abil
host
deal
infect
seen
lymphocyt
number
andor
viral
titer
lung
unchang
conclus
compound
target
differ
step
neutrophil
activ
migrat
import
therapeut
potenti
investig
human
matthew
esparza
univers
texa
southwestern
medic
centr
dalla
tx
usa
urgent
need
develop
new
treatment
influenza
viru
infect
one
approach
directli
target
host
factor
involv
essenti
viral
function
without
caus
major
effect
host
cell
influenza
viru
genom
contain
vrna
segment
vrna
segment
code
matrix
protein
splice
variant
mrna
also
altern
splice
encod
ion
channel
previous
shown
posttranscript
splice
fulllength
mrna
occur
nuclear
speckl
special
storag
site
splice
factor
insid
nucleu
mrna
export
nucleu
cytoplasm
translat
protein
necessari
viral
traffick
gener
new
viral
particl
sinc
cellular
mrna
splice
nuclear
speckl
inhibit
splice
viral
mrna
present
possibl
avenu
develop
new
class
antivir
inhibitor
high
throughput
chemic
screen
perform
start
compound
identifi
small
molecul
effector
viral
mrna
splice
nuclear
export
use
multistep
approach
compound
show
strong
inhibit
mrna
splice
nuclear
export
activ
toward
bulk
poli
rna
nuclear
export
toxic
host
cell
identifi
two
influenza
inhibitor
identifi
differ
phenotyp
one
compound
inhibit
subset
influenza
strain
present
broad
antivir
activ
provid
promis
lead
drug
develop
isabel
najera
virion
biotherapeut
ltd
london
uk
novel
broadspectrum
antivir
agent
dual
mechan
action
first
novel
class
antivir
call
therapeut
interf
particl
mutant
nonrepl
viru
particl
dimmock
et
al
model
defect
interf
influenza
viral
particl
occur
natur
typic
contain
highli
delet
form
viral
genom
unabl
replic
develop
treatment
multipl
respiratori
viral
infect
effect
moieti
deriv
segment
influenza
truncat
nucleotid
rna
packag
within
viral
particl
deriv
influenza
enter
host
cell
effici
result
nonproduct
infect
replic
lack
fulllength
segment
encod
essenti
compon
rna
polymeras
complex
significantli
reduc
replic
respiratori
virus
vitro
two
separ
mechan
action
panrespiratori
viral
infect
activ
respiratori
virus
includ
influenza
b
pneumonia
viru
mice
pvm
rsv
human
rhinoviru
hrv
stimul
host
innat
immun
activ
cell
antivir
state
influenza
genom
interfer
efficaci
demonstr
vitro
vivo
murin
ferret
model
influenza
given
prophylact
studi
therapeut
efficaci
evalu
pvm
surrog
murin
model
rsv
earli
administr
singl
dose
day
postinfect
protect
mice
sign
diseas
signific
weight
loss
later
administr
day
provid
less
protect
diseas
weight
loss
efficaci
given
start
day
postinfect
also
demonstr
high
barrier
emerg
viral
drug
resist
prolong
vivo
passag
experi
expand
therapeut
window
protect
offer
possibl
may
provid
effect
treatment
respiratori
viral
infect
even
treatment
delay
current
licens
treatment
influenza
effect
given
within
h
symptom
onset
current
late
stage
preclin
develop
ralf
altmey
shandong
univers
qingdao
china
rsv
transcript
antitermin
factor
identifi
new
target
rsv
therapeut
intervent
potent
select
chemic
inhibitor
identifi
seri
eleg
mode
action
studi
rsv
report
construct
mutant
rsv
viru
singl
point
mutat
evalu
seri
chemic
probe
base
cyclopamin
cyclopamin
steroid
alkaloid
smoothen
receptor
smo
antagonist
inhibit
rsv
replic
also
undesir
offtarget
effect
interact
hedgehog
pathway
impact
import
biolog
process
host
cell
address
issu
chemic
analogu
cyclopamin
design
use
structur
cyclopaminesmo
synthes
test
determin
antirsv
activ
rsv
could
separ
unwant
smomedi
signal
activ
compound
test
inhibit
essenti
function
rsv
replic
format
inclus
bodi
associ
granul
ibag
timeofaddit
studi
cyclopamin
show
target
postentri
phase
viral
replic
reduc
transcript
downstream
gene
rsv
replic
ibag
format
disrupt
sever
smo
rsv
molecul
identifi
abl
specif
suppress
rsv
lung
infect
mous
model
dosedepend
manner
target
valid
studi
conduct
use
rsv
minireplicon
system
revers
genet
recombin
rsv
express
luciferas
report
gene
mutant
rsv
viru
singl
mutat
chemic
analog
data
show
hedgehog
rsv
activ
cyclopamin
dissoci
pave
way
develop
new
molecular
entiti
target
base
cyclopamin
scaffold
eain
murphi
forg
life
scienc
doylestown
pa
usa
intracellular
pathogen
depend
manipul
host
cell
metabol
energi
metabol
precursor
regul
host
cell
metabol
fundament
compon
hostviru
interact
viabl
target
antivir
intervent
team
interest
develop
small
molecul
drug
modul
hostencod
sirtuin
protein
enzym
regul
hostcel
metabol
gene
activ
deacyl
downstream
target
protein
critic
viral
replic
lead
compound
select
medicin
chemistri
seri
relat
compound
effect
viral
growth
influenza
human
cytomegalovirus
hcmv
ic
nm
low
cytotox
select
index
demonstr
emerg
viral
resist
success
serial
passag
experi
administr
inhibitor
led
select
apoptosi
cell
infect
influenza
reduc
express
cmyc
oncogen
recruit
influenza
activ
glutamin
metabol
nucleosid
biosynthesi
modul
hostsirtuin
activ
infect
provid
effect
broadspectrum
antivir
limit
viral
replic
rna
virus
like
influenza
b
well
dna
virus
like
hcmv
clinic
outcom
endpoint
respiratori
viral
illnesslearn
past
john
beigel
niaid
bethesda
md
usa
primari
outcom
measur
definit
trial
clinic
event
relev
patient
templ
endpoint
measur
directli
patient
feel
function
surviv
us
food
drug
administr
function
refer
patient
abil
perform
activ
daili
live
registr
trial
therapeut
acut
uncompl
influenza
use
durat
defin
influenza
symptom
primari
endpoint
howev
choic
endpoint
clear
conduct
trial
popul
hospit
sever
influenza
could
patient
feel
use
popul
hospit
influenza
studi
popul
oxygen
intens
care
unit
mechan
ventil
beigel
et
al
limit
capabl
answer
patient
report
outcom
would
fulli
reflect
hospit
popul
use
mortal
endpoint
prior
studi
sever
influenza
mortal
rate
beigel
et
al
low
hospit
influenza
studi
de
jong
et
al
rate
signific
public
health
concern
demonstr
improv
rate
requir
sampl
size
exceed
particip
mortal
feasibl
primari
outcom
trial
endpoint
popul
therefor
need
focu
patient
function
fda
guidanc
suggest
serious
ill
influenza
patient
requir
hospit
primari
endpoint
includ
clinic
sign
symptom
durat
hospit
time
normal
vital
sign
oxygen
requir
supplement
oxygen
assist
ventil
mortal
us
food
drug
administr
meet
requir
prior
studi
evalu
differ
endpoint
trial
identifi
popul
hospit
influenza
use
ordin
scale
primari
endpoint
use
time
clinic
resolut
use
resolut
tachypnea
hypoxia
endpoint
resolut
tachypnea
hypoxia
note
signific
variat
throughout
day
studi
particip
resolv
hypoxia
random
prior
treatment
beigel
et
al
time
clinic
resolut
often
driven
measur
case
peramivir
larg
driven
resolut
fever
de
jong
et
al
ultim
nt
meet
fda
requir
focus
patient
function
therefor
recent
sponsor
turn
attent
use
ordin
scale
clinic
statu
day
endpoint
clinic
meaning
minim
variat
yet
success
use
pivot
studi
michael
ison
northwestern
univers
chicago
il
usa
choic
endpoint
therapeut
studi
respiratori
viral
diseas
depend
clinic
set
popul
studi
prior
guidanc
fda
note
singl
best
endpoint
identifi
serious
ill
hospit
patient
sponsor
encourag
provid
evid
abil
propos
endpoint
directli
measur
patient
feel
function
surviv
us
food
drug
administr
order
construct
endpoint
need
better
categor
sever
diseas
hospit
respiratori
viru
nation
earli
warn
score
news
develop
unit
kingdom
identifi
patient
risk
deterior
escal
care
sever
studi
use
propos
use
news
defin
popul
sever
influenza
score
valid
purpos
retrospect
studi
conduct
northwestern
univers
hospit
evalu
patient
hospit
influenza
categor
news
ordin
scale
clinic
outcom
death
icu
mechan
ventil
icu
mechan
ventil
hospit
supplement
oxygen
hospit
supplement
oxygen
discharg
resum
normal
activ
discharg
resumpt
normal
activ
prior
studi
demonstr
earli
treatment
led
better
clinic
outcom
use
surrog
therapeut
benefit
antivir
current
analysi
analyz
use
ordin
scale
endpoint
higher
baselin
news
associ
greater
later
therapeut
benefit
neuraminidas
inhibitor
nai
base
treatment
howev
recruit
may
affect
fewer
number
patient
news
increas
ison
separ
retrospect
analysi
patient
hospit
influenza
compar
clinic
outcom
day
durat
ill
prior
treatment
h
onset
symptom
vs
h
analysi
abl
demonstr
mean
score
ordin
compon
statist
differ
hospit
day
suggest
may
day
use
assess
ordin
scale
therapeut
studi
lastli
use
data
beigel
et
al
ordin
scale
assess
studi
day
common
odd
ratio
signific
day
p
analyz
durat
symptom
prior
treatment
day
vs
day
differ
mean
score
ordin
endpoint
pronounc
studi
day
king
cumul
data
suggest
news
differenti
sever
popul
inclus
therapeut
studi
use
ordin
scale
assess
around
day
lorant
leopold
janssen
pharma
r
titusvil
nj
usa
hospit
recoveri
scale
hr
name
given
specif
ordin
scale
use
phase
trial
pimodivir
scale
categor
particip
clinic
function
characterist
death
icu
mechan
ventil
hospit
supplement
oxygen
hospit
supplement
oxygen
discharg
resum
normal
activ
discharg
resumpt
normal
activ
phase
studi
pimodivir
opal
enrol
particip
age
year
hospit
influenza
random
receiv
pimodivir
mg
twice
daili
plu
oseltamivir
vs
oseltamivir
alon
day
studi
common
odd
ratio
ordin
scale
outcom
particip
show
benefit
analyz
h
symptom
feedback
regul
object
subject
observ
mix
interprovid
variat
criteria
hospit
admissiondischarg
icu
admissiondischarg
account
scale
also
convey
studi
must
evalu
key
secondari
endpoint
would
expect
mirror
benefit
demonstr
ordin
scale
phase
studi
pimodivir
use
differ
ordin
scale
ordin
endpoint
death
mechan
ventil
icu
mechan
ventil
hospit
supplement
oxygen
hospit
supplement
oxygen
discharg
ordin
scale
use
pivot
studi
sponsor
consid
incorpor
regulatori
feedback
design
ordin
scale
suyoung
choi
fda
silver
spring
md
usa
design
clinic
trial
influenza
rsv
requir
optim
dose
regimen
balanc
benefit
risk
clinic
pharmacolog
scienc
understand
interpati
variabl
bodi
drug
pharmacokinet
pk
drug
bodi
pharmacodynam
pd
allow
clear
understand
absorpt
distribut
metabol
excret
adm
essenti
identifi
optim
drug
dose
time
patient
popul
studi
pharmacolog
drug
treat
respiratori
viral
diseas
present
sever
uniqu
challeng
first
complex
limit
knowledg
pkpd
lung
compar
organ
requir
care
select
optim
pharmacolog
tool
ensur
accur
assess
second
special
consider
given
product
deliv
via
inhal
rout
distinct
adm
characterist
borghardt
et
al
lipworth
olsson
et
al
third
differ
pharmacolog
assess
need
depend
whether
drug
small
molecul
complex
therapeut
protein
monoclon
antibodi
us
food
drug
administr
fourth
measur
drug
concentr
site
action
bronchoalveolar
difficult
may
necessit
measur
site
potenti
activ
includ
blood
nasal
wash
fifth
challeng
translat
vitro
preclin
efficaci
influenza
rsv
antivir
human
efficaci
expect
challeng
becom
even
complic
studi
progress
pediatr
age
group
rsv
infect
occur
influenza
infect
becom
seriou
us
food
drug
administr
similar
challeng
expect
influenza
drug
develop
pregnant
women
beigi
et
al
greer
et
al
fortun
ongo
advanc
field
clinic
pharmacolog
expect
make
develop
respiratori
antivir
therapi
effici
exampl
improv
model
simul
approach
effici
optim
respiratori
antivir
therapi
viral
kinet
model
identifi
target
viral
replic
pkpd
model
use
select
optim
durat
dose
prevent
emerg
drug
resist
physiolog
base
pk
model
approach
util
studi
local
pulmonari
pk
pd
michel
campbel
fda
silver
spring
md
usa
evalu
posit
clinic
meaning
effect
treatment
hospit
patient
influenza
sever
acut
respiratori
infect
sari
essenti
consid
patient
feel
function
surviv
feedback
may
impact
approv
decis
fda
provid
import
inform
label
clinic
outcom
assess
coa
includ
differ
tool
collect
subject
feedback
includ
patientreport
outcom
pro
clinicianreport
outcom
clinro
observerreport
outcom
obsro
perform
outcom
perfro
addit
standard
form
data
digit
health
technolog
also
use
collect
coa
regardless
type
coa
use
appropri
intend
use
patient
popul
studi
design
fitforpurpos
concept
reliabl
measur
clinic
import
valuabl
patient
commun
label
way
accur
interpret
welldefin
assist
process
fda
publish
guidanc
industri
plan
use
coa
hospit
patient
influenza
sari
select
endpoint
consid
decis
made
whether
particular
pro
best
tool
whether
anoth
coa
select
addit
consider
choos
coa
includ
whether
one
coa
use
measur
recoveri
discharg
coa
use
across
cultur
languag
reproduc
within
across
rater
assist
answer
question
fda
develop
sever
pathway
assess
review
advic
whether
plan
develop
program
individu
drug
develop
novel
coa
use
multipl
program
one
pathway
critic
path
innov
meet
gener
nonbind
advic
sought
specif
methodolog
technolog
earli
stage
develop
us
food
drug
administr
conclus
fda
support
develop
implement
patient
coa
clinic
trial
support
drug
approv
label
claim
encourag
earli
commun
agenc
provid
advic
select
modif
develop
appropri
coa
kimberli
armstrong
barda
washington
dc
usa
clinic
trial
hospit
patient
challeng
organ
enrol
influenza
season
mean
season
enrol
per
clinic
site
limit
approxim
six
week
peak
activ
cover
two
week
averag
addit
one
third
hospit
clinic
site
enrol
singl
patient
anoth
quarter
enrol
one
two
subject
beigel
et
al
de
jong
et
al
marti
et
al
facilit
adequ
enrol
larg
number
site
across
globe
requir
complet
studi
time
manner
howev
global
variabl
clinic
care
standard
care
soc
pose
consider
challeng
studi
design
interpret
generaliz
anoth
challeng
occur
enrol
span
multipl
season
make
difficult
compar
across
vari
strain
differ
clinic
present
addit
agre
upon
clinic
endpoint
hospit
influenza
clinic
studi
poor
correl
viral
load
clinic
symptom
make
clinic
endpoint
rather
virolog
endpoint
logic
howev
subject
natur
clinic
endpoint
along
variabl
soc
requir
region
differ
qualiti
healthcar
make
harder
determin
real
effect
treatment
furthermor
mani
countri
institut
review
board
ethic
committe
requir
hospitalbas
phase
clinic
trial
use
soc
oseltamivir
addit
investig
drug
compar
soc
alon
yang
et
al
therefor
investig
drug
must
demonstr
superior
oseltamivir
meet
endpoint
studi
factor
creat
signific
challeng
trial
design
increas
irregular
data
collect
one
final
obstacl
cost
trial
cost
well
per
patient
enrol
rel
small
popul
gain
label
indic
hospit
influenza
compar
acut
uncompl
influenza
high
bar
superior
perpati
cost
make
difficult
sponsor
justifi
conduct
trial
popul
possibl
solut
would
requir
close
collabor
industri
academia
govern
could
includ
clinic
trial
innov
improv
simplifi
enrol
trial
design
adequ
intellectu
monetari
compens
academ
site
work
fda
modifi
regulatori
approach
toward
approv
influenza
drug
oral
avail
broadspectrum
antiinfluenza
ribonucleosid
analog
inhibitor
potent
efficaci
ferret
differenti
human
airway
epithelia
richard
plemper
georgia
state
univers
atlanta
ga
usa
identif
broadspectrum
therapeut
effect
welltoler
treatment
rsv
influenza
infect
would
benefici
virus
respons
bulk
influenzalik
ill
approach
taken
identifi
promis
broadspectrum
antivir
candid
outlin
initi
high
throughput
screen
ht
assay
use
librari
contain
compound
screen
valid
replicationcompet
influenza
viru
iav
report
viru
screen
yield
broad
spectrum
ribonucleosid
inhibitor
activ
rsv
influenza
use
round
test
panel
laboratoryadapt
clinic
strain
repres
rsv
iav
influenza
b
virus
ibv
establish
cell
line
primari
human
bronchial
tracheal
epitheli
cell
hbtec
shown
activ
influenza
group
strain
includ
pathogen
avian
influenza
isol
influenza
b
submicromolar
rang
put
mechan
action
induct
viru
error
catastroph
inabl
replic
result
excess
mutat
experiment
data
show
high
barrier
resist
resist
virus
identifi
ten
passag
deep
sequenc
viru
popul
optim
oral
bioavail
nonhuman
primat
prodrug
develop
greatli
improv
drug
uptak
higher
mammal
efficaci
test
use
ferret
model
influenza
infect
demonstr
low
toxic
potent
efficaci
prodrug
outlin
broad
therapeut
window
initi
dose
mgkg
either
prophylact
administ
post
exposur
show
reduct
viral
load
sever
order
magnitud
nasal
lavag
dose
h
post
infect
mgkg
mgkg
test
influenza
group
strain
influenza
b
strain
result
equival
reduct
viral
load
order
magnitud
within
h
administr
first
dose
clinic
sign
fever
airway
tissu
damag
significantli
allevi
applic
pharmacokinet
profil
vitro
studi
welldifferenti
human
airliquid
interfac
airway
epithelium
model
reveal
steril
efficaci
toxic
threshold
primari
human
tissu
inform
predict
drug
concentr
target
clinic
trial
yoon
et
al
waitat
wong
chines
univers
hong
kong
hong
kong
sar
china
clinic
studi
shown
earlier
treatment
oseltamivir
benefici
term
reduc
mortal
even
situat
treatment
delay
world
health
organ
recommend
oseltamivir
dose
doubl
higher
treat
case
sever
influenza
howev
clinic
studi
shown
oseltamivir
dose
increas
twofold
mg
compar
standard
dose
mg
differ
observ
primari
outcom
viral
clearanc
goal
studi
ascertain
treat
sever
ill
influenza
posit
patient
increas
oseltamivir
dose
would
show
clinic
benefit
open
label
studi
influenzaposit
patient
icu
mechan
ventil
random
treatment
group
consist
patient
receiv
either
doubl
mg
tripl
dose
mg
oseltamivir
respect
primari
outcom
rate
viral
clearanc
day
secondari
outcom
given
mortal
patient
influenza
posit
bacteri
coinfect
acut
physiolog
chronic
health
evalu
apach
sever
score
greater
difficulti
encount
recruit
patient
due
high
rate
renal
failur
result
studi
show
statist
signific
differ
treatment
group
either
primari
secondari
endpoint
small
differ
viral
load
nasopharyng
tracheal
aspir
observ
higher
dose
oseltamivir
howev
differ
statist
signific
similarli
differ
observ
mortal
keiko
baba
shionogi
co
ltd
osaka
japan
number
nai
approv
treatment
influenza
infect
baloxavir
new
class
therapeut
target
capdepend
endonucleas
influenza
b
virus
use
baloxavir
combin
nai
may
provid
addit
clinic
benefit
resolv
infect
influenza
b
viru
studi
undertaken
assess
synergist
effect
influenza
b
viru
replic
vitro
nai
baloxavir
mix
concentr
close
ec
valu
experiment
approach
involv
evalu
compound
individu
cytopath
effect
assay
rang
three
nai
ec
nmoll
baloxavir
nmoll
use
chou
talalay
method
combin
index
gener
base
experiment
data
observ
effect
classifi
addit
nai
data
complement
previous
publish
studi
show
synergist
effect
influenza
viru
replic
baloxavir
use
combin
nai
fukao
et
al
philipp
noriel
pascua
st
jude
children
research
hospit
memphi
tn
usa
immunocompromis
patient
suscept
infect
influenza
prolong
viral
shed
elev
risk
complic
murin
model
develop
recapitul
chronic
infect
observ
immunocompromis
patient
test
investig
approv
therapeut
agent
genet
modifi
immunocompromis
balb
scid
mice
infect
influenza
b
viru
display
suscept
infect
persist
viral
replic
recapitul
chronic
infect
efficaci
repres
nai
peramivir
rnadepend
rna
polymeras
inhibitor
favipiravir
assess
use
balbc
balb
scid
mice
pascua
et
al
start
h
postinfect
peramivir
mgkgday
administ
mice
intramuscularli
im
everi
day
group
receiv
singl
doubl
quadrupl
dose
favipiravir
administ
oral
mgkgday
twice
daili
day
observ
control
balbc
mice
succumb
infect
treat
peramivir
surviv
scid
mice
anim
receiv
dose
peramivir
surviv
compar
onedosetr
group
viru
replic
examin
lung
nasal
turbin
oneand
twodos
group
peramivir
suppress
viru
replic
lower
respiratori
tract
lrt
requir
two
treatment
suppress
replic
nasal
turbin
balbc
mice
contrast
peramivir
suppress
viral
replic
turbin
lung
scid
mice
balbc
mice
treat
mgkgday
dose
favipiravir
significantli
increas
surviv
rate
suppress
viral
replic
lung
howev
suppress
viral
replic
nasal
turbin
observ
anim
dose
mg
kgday
scid
mice
administr
mgkgday
result
surviv
similar
trend
observ
effect
suppress
viral
replic
nasal
turbin
neither
agent
abl
suppress
replic
upper
respiratori
tract
establish
immunocompromis
murin
model
influenza
b
viru
infect
facilit
evalu
efficaci
current
avail
investig
antiinfluenza
drug
immunocompromis
popul
pascua
et
al
vitro
antivir
assess
monoclon
antibodi
influenza
viru
combin
baloxavir
neuraminidas
inhibitor
kristin
narayan
visterra
inc
waltham
usa
broadli
activ
monoclon
antibodi
bind
ha
stalk
influenza
viru
strain
clinic
develop
treatment
critic
ill
hospit
patient
target
earli
step
infect
cycl
fusion
bind
neutral
viru
along
promot
antibodydepend
cellular
cytotox
adcc
antibodydepend
cellular
phagocytosi
adcp
activ
antivir
activ
assess
context
polymorph
within
ha
epitop
combin
approv
antiviralsoseltamivir
peramivir
zanamivir
baloxavir
assess
impact
polymorph
within
ha
epitop
sequenc
current
circul
strain
cover
year
obtain
global
initi
share
influenza
data
gsaid
databas
approxim
influenza
sequenc
analyz
chang
epitop
mostli
chang
amino
acid
frequenc
posit
compris
epitop
howev
chang
ha
posit
l
v
observ
low
frequenc
last
season
full
length
clone
express
surfac
cell
facilit
bind
analysi
use
flow
cytometri
cell
express
v
l
show
signific
chang
bind
consid
hospit
patient
given
nai
soc
along
recent
approv
baloxavir
acut
influenza
impact
use
small
molecular
antivir
combin
assess
cellbas
vitro
infect
assay
adapt
world
health
organ
protocol
use
evalu
individu
compound
activ
use
combin
improv
antivir
activ
use
combin
baloxavir
influenza
virus
likewis
inclus
result
improv
antivir
activ
baloxavir
present
suboptim
level
close
baloxavir
antivir
ec
synergi
analysi
show
clear
synergi
baloxavir
influenza
minor
antagon
observ
highest
drug
concentr
may
repres
technic
artifact
caus
reach
maximum
antivir
effect
dose
combin
individu
nai
oseltamivir
peramivir
zanamivir
also
show
synergi
addit
effect
ec
individu
compound
composit
peptid
conjug
vaccin
induc
broadli
reactiv
serum
monoclon
antibodi
influenza
clara
j
sei
longhorn
vaccin
diagnost
llc
gaithersburg
md
usa
composit
peptid
vaccin
may
provid
advantag
term
eas
manufactur
level
cross
protect
differ
strain
influenza
viru
composit
peptid
vaccin
consist
peptid
sequenc
deriv
conserv
region
influenza
ha
neuraminidas
na
matrix
ectodomain
protein
immun
respons
two
vaccin
candid
assess
mice
abil
elicit
broadli
reactiv
neutral
serum
antibodi
peptid
conjug
carrier
protein
known
cross
react
materi
crm
nontox
variant
diphtheria
toxin
dt
peptid
crmconjug
vaccin
administ
subcutan
prime
boost
live
influenza
wuhan
administ
intramuscularli
dose
prime
live
influenza
viru
day
mice
inject
subcutan
peptid
composit
vaccin
day
immunolog
respons
assess
use
individu
peptid
virus
includ
influenza
initi
immunolog
respons
low
becam
robust
time
peak
day
second
subunit
vaccin
composit
vaccin
contain
peptid
sequenc
tetanu
tcell
epitop
sequenc
conjug
crm
vaccin
administ
subcutan
prime
boost
mice
given
boost
day
robust
immun
respons
observ
start
day
maxim
day
base
analyt
result
conclud
peptid
composit
vaccin
highli
immunogen
elicit
strong
humor
respons
mice
monoclon
antibodi
mab
isol
character
assess
bind
profil
rang
influenza
strain
monoclon
antibodi
identifi
bound
individu
composit
peptid
live
virus
also
show
cross
neutral
potenti
influenza
microneutr
assay
mab
along
monoclon
antibodi
bind
ha
na
protein
evalu
antibodydepend
cellular
cytotox
adcc
activ
two
random
doubleblind
placebocontrol
trial
monoclon
antibodi
treatment
influenza
infect
melic
peck
genentech
south
san
francisco
ca
usa
human
immunoglobulin
monoclon
antibodi
bind
highli
conserv
epitop
stalk
influenza
ha
gupta
et
al
phase
human
influenza
viru
challeng
studi
show
signific
reduct
clinic
symptom
viral
burden
rel
placebo
mcbride
et
al
two
addit
phase
random
doubleblind
placebocontrol
trial
treatment
influenza
infect
util
conduct
nighthawk
studi
enrol
otherwis
healthi
adult
outpati
influenza
present
within
day
influenza
symptom
onset
subject
random
receiv
singl
iv
dose
placebo
mg
mg
primari
endpoint
safeti
time
allevi
clinic
sign
symptom
influenza
median
time
allevi
total
influenzarel
symptom
lower
placebo
h
activ
treatment
arm
h
mg
h
mg
differ
statist
signific
significantli
reduc
time
clearanc
viral
load
crane
studi
enrol
hospit
adult
patient
influenza
requir
supplement
oxygen
posit
pressur
ventil
present
within
day
influenza
symptom
onset
within
h
hospit
admiss
subject
random
receiv
oseltamivir
combin
iv
placebo
mg
mg
primari
endpoint
time
cessat
oxygen
support
stabl
spo
nasopharyng
sampl
assess
qpcr
influenza
viral
load
median
time
cessat
oxygen
support
day
oseltamivir
group
compar
day
p
day
p
mg
mg
treatment
group
respect
allcaus
mortal
overal
low
significantli
differ
arm
oseltamivir
group
mg
mg
oseltamivir
group
respect
day
icu
discharg
ventil
remov
favor
oseltamivir
group
statist
signific
statist
signific
differ
primari
secondari
object
time
clearanc
viral
load
placebo
treat
group
overal
safe
welltoler
healthi
outpati
influenza
infect
combin
oseltamivir
demonstr
clinic
benefit
oseltamivir
alon
hospit
patient
sever
influenza
infect
takeki
uehara
shionogi
co
ltd
osaka
japan
baloxavir
marboxil
recent
fdaapprov
select
inhibitor
influenza
capdepend
endonucleas
essenti
enzym
viral
replic
although
baloxavir
found
potent
activ
varieti
influenza
virus
variant
amino
acid
substitut
posit
polymeras
acid
protein
produc
higher
ec
baloxavir
vitro
incid
treatmentemerg
substitut
variant
adult
rang
xofluza
pediatricfocus
studi
show
rel
higher
frequenc
takashita
et
al
phase
trial
otherwis
healthi
patient
year
old
uncompl
influenza
demonstr
baloxavir
significantli
reduc
viral
titer
time
allevi
symptom
tta
compar
placebo
clinic
benefit
baloxavir
observ
regardless
variant
statu
clear
associ
emerg
pa
variant
exacerb
clinic
outcom
phase
trial
highrisk
patient
uncompl
influenza
demonstr
baloxavir
welltoler
associ
faster
recoveri
reduc
risk
complic
highrisk
influenza
patient
compar
placebo
baloxavir
superior
oseltamivir
shorten
durat
viral
shed
influenza
b
viru
resolv
influenza
bassoci
ill
ison
et
al
variant
found
patient
enrol
studi
emerg
pa
result
longer
time
improv
influenza
symptom
portsmouth
section
phase
studi
pediatr
patient
year
old
demonstr
clinic
outcom
baloxavir
compar
adult
pediatr
patient
variant
appear
longer
time
allevi
symptom
lower
baselin
viral
antibodi
titer
shown
increas
risk
variant
emerg
whether
emerg
variant
may
associ
prolong
viral
shed
ill
seriou
influenza
requir
care
futur
studi
rsv
antivir
treatment
hct
patient
result
recent
phase
studi
presatovir
michael
boeckh
univers
washington
seattl
wa
usa
potent
small
molecul
inhibitor
target
rsv
f
protein
inhibit
f
proteinmedi
celltocel
fusion
perron
et
al
prior
studi
healthi
adult
challeng
intranas
rsv
demonstr
reduc
viral
load
sever
clinic
diseas
phase
studi
conduct
hematopoiet
stem
cell
transplant
hsct
recipi
either
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
urti
studi
enrol
rsvposit
patient
lrti
studi
enrol
patient
allow
option
extend
viral
load
followup
day
primari
endpoint
urti
lrti
studi
includ
chang
nasal
rsv
viral
load
coprimari
endpoint
urti
studi
develop
lower
respiratori
tract
complic
day
secondari
endpoint
studi
proport
patient
develop
respiratori
failur
requir
mechan
ventil
allcaus
mortal
day
lrti
studi
also
includ
number
supplement
oxygen
free
day
urti
patient
treat
demonstr
signific
decreas
timeweight
averag
nasal
rsv
viral
load
day
measur
rtqpcr
compar
placebo
treatment
differ
p
signific
decreas
observ
lrti
group
treatment
differ
p
urti
lrti
studi
demonstr
signific
effect
secondari
endpoint
respiratori
failur
allcaus
mortal
signific
differ
observ
number
mean
supplement
oxygen
free
day
lrti
studi
well
patient
urti
treat
demonstr
consist
trend
toward
reduc
lower
respiratori
tract
complic
progress
rate
vs
p
especi
among
patient
earli
urti
cours
hospit
dose
vs
p
lymphopenia
vs
p
sever
newli
identifi
treatmentemerg
substitut
e
nv
fw
found
map
interact
site
rsv
f
may
involv
resist
overal
although
decreas
nasal
rsv
viral
load
urti
patient
reach
prespecifi
threshold
signific
primari
secondari
endpoint
therefor
treatment
unlik
benefici
infect
alreadi
evolv
lrti
offer
potenti
treatment
benefit
patient
urti
high
risk
poor
rsvrelat
outcom
lower
respiratori
tract
complic
present
earli
diseas
cours
jame
witek
janssen
research
develop
titusvil
nj
usa
respiratori
infect
influenza
rsv
continu
grow
concern
new
treatment
urgent
need
janssen
respiratori
program
focus
develop
vaccin
biolog
diagnost
antivir
therapeut
rsv
influenza
patient
rsv
multipl
asset
develop
includ
target
rsv
fusion
process
activ
rsv
rna
polymeras
lumicitabin
oral
nucleosid
analog
previous
demonstr
proof
concept
human
rsv
challeng
model
devincenzo
et
al
singl
multipl
ascend
dose
studi
infant
hospit
rsv
infect
recent
complet
result
show
grade
treatmentemerg
neutrophil
abnorm
eudract
number
clinic
trial
current
close
ongo
analysi
addit
new
nonclin
data
smallmolecul
rsv
fusion
inhibitor
establish
clinic
proof
concept
phase
adult
rsv
challeng
studi
phase
studi
hospit
infant
martinontorr
et
al
two
phase
studi
adult
infant
initi
clinicaltrialsgov
identifi
nonnucleosid
polymeras
inhibitor
current
undergo
phase
healthi
volunt
studi
clinicaltrialsgov
identifi
develop
rsv
vaccin
also
ongo
phase
studi
evalu
safeti
toler
immunogen
adenoviru
serotyp
base
rsv
prefus
f
protein
rsvpref
vaccin
current
ongo
older
adult
rsvseroposit
toddler
clinicaltrialsgov
identifi
influenza
therapeut
develop
focus
target
influenza
viru
replic
complex
capbindingfus
mechan
pimodivir
capbind
inhibitor
undergon
phase
studi
includ
combin
oseltamivir
ambulatori
hospit
patient
finberg
et
al
mckimmbreschkin
et
al
result
demonstr
potenti
valu
combin
oseltamivir
phase
studi
current
underway
clinicaltrialsgov
identifi
develop
pa
endonucleas
inhibitor
discontinu
earli
phase
studi
identifi
inabl
establish
singl
safe
effect
dose
across
patient
current
drug
develop
includ
multidomain
antibodi
contain
four
influenza
ab
habind
domain
laursen
et
al
random
phase
studi
evalu
nitazoxanid
versu
placebo
hospit
subject
sever
acut
respiratori
ill
john
beigel
niaid
bethesda
md
usa
nitazoxanid
ntz
small
inhibitor
use
extens
treatment
giardia
cryptosporidium
infect
explor
treatment
influenza
influenzalik
ill
ili
rossignol
shakya
et
al
parainfluenza
piv
rsv
canin
coronaviru
rhinoviru
influenza
haffizulla
et
al
piacentini
et
al
rossignol
stachulski
et
al
moreov
ntz
shown
synergist
oseltamivir
zanamivir
belardo
et
al
march
march
doubleblind
placebocontrol
trial
conduct
particip
year
age
hospit
influenzalik
ill
ili
six
hospit
mexico
particip
random
ntz
year
old
mg
twice
daili
year
old
mg
twice
daili
respect
placebo
day
addit
soc
gaminoarroyo
et
al
primari
endpoint
time
hospit
discharg
particip
enrol
random
took
least
one
dose
studi
treatment
median
durat
hospit
ntz
group
day
versu
day
placebo
group
p
durat
hospit
two
treatment
group
similar
children
p
adult
p
influenza
b
p
respiratori
virus
particip
receiv
ntz
report
advers
event
compar
particip
receiv
placebo
advers
event
conclus
treatment
ntz
safe
reduc
durat
hospit
stay
sever
influenzalik
ill
wendi
carter
lare
traci
fda
silver
spring
md
usa
despit
signific
clinic
impact
influenza
year
current
therapeut
option
influenza
fda
approv
acut
uncompl
case
remain
pauciti
data
regard
safe
effect
treatment
seriou
influenza
infect
hospit
patient
random
control
trial
rct
novel
therapeut
combin
soc
therapi
versu
soc
alon
hospit
influenza
fail
demonstr
signific
superior
compar
soc
de
jong
et
al
marti
et
al
rct
limit
enrol
highli
heterogen
hospit
popul
experienc
difficulti
patient
enrol
use
standard
assess
consist
measur
severityofil
may
help
identifi
homogen
trial
popul
serious
ill
due
influenza
infect
one
exampl
clinic
severityofil
scale
nation
earli
warn
score
royal
colleg
physician
howev
still
requir
prospect
evalu
use
popul
addit
use
severityofil
scale
elig
criteria
use
supplement
oxygen
respiratori
support
influenzarel
condit
may
also
use
target
appropri
trial
popul
enrol
clinic
benefit
therapeut
may
demonstr
develop
novel
therapeut
treatment
seriou
influenza
hospit
patient
also
hinder
lack
data
support
particular
best
endpoint
indic
futur
trial
may
consid
addit
endpoint
time
clinic
resolut
symptom
endpoint
use
prior
rct
exampl
ordin
endpoint
compris
protocoldefin
explicit
mutual
exclus
order
state
current
evalu
trial
evalu
pimodivir
clinicaltrialsgov
id
uncertainti
remain
regard
appropri
time
assess
whether
ordin
scale
consid
clinicallymeaning
final
fda
consid
altern
primari
endpoint
seriou
hospit
influenza
sponsor
encourag
submit
develop
propos
howev
endpoint
requir
valid
demonstr
measur
patient
feel
function
surviv
radu
botgro
ema
london
uk
rsv
one
import
caus
lower
respiratori
tract
infect
lrti
infant
elderli
worldwid
anderson
et
al
falsey
et
al
current
approv
treatment
option
infant
limit
inhal
ribavirin
eu
member
state
palivizumab
prevent
high
risk
infant
subgroup
european
medicin
agenc
ema
committe
medicin
product
human
use
chmp
recent
adopt
publish
guidanc
clinic
evalu
medicin
product
indic
prophylaxi
treatment
rsv
diseas
guidanc
cover
develop
vaccin
monoclon
antibodi
prevent
rsv
diseas
directact
antivir
agent
daa
treatment
rsv
diseas
european
medicin
agenc
focu
assess
safeti
efficaci
popul
like
develop
rsv
lrti
sever
rsv
diseas
includ
infant
toddler
age
day
month
older
adult
eg
age
year
candid
daa
doubleblind
superior
trial
candid
daa
versu
uncontrol
group
base
clinic
relev
primari
endpoint
current
feasibl
may
need
reconsider
futur
also
essenti
clear
definit
rsv
case
base
combin
clinic
laboratori
criteria
regard
influenza
sever
scientif
advic
request
receiv
last
year
chmp
guidanc
avail
yet
nai
becom
soc
sever
influenza
hospit
patient
despit
fact
definit
clinic
benefit
yet
shown
random
studi
popul
expert
consensu
appropri
clinic
endpoint
sever
influenza
need
futur
studi
possibl
studi
design
daa
includ
consider
demonstr
superior
soc
includ
nai
part
soc
superior
addon
versu
placebo
new
agent
nai
vs
nai
alon
resist
pattern
monitor
conduct
clinic
trial
daa
michael
ison
northwestern
univers
chicago
il
usa
current
approv
antivir
drug
influenza
approv
base
data
demonstr
faster
time
resolut
influenzarel
symptom
low
risk
outpati
popul
dobson
et
al
studi
success
conduct
highrisk
popul
endpoint
drug
approv
must
demonstr
superior
improv
patient
feel
function
surviv
assess
endpoint
proven
challeng
hospit
patient
immunocompromis
popul
ison
et
al
phase
trial
evalu
iv
peramivir
compar
placebo
highlight
challeng
adequ
patient
enrol
de
jong
et
al
although
subject
screen
clinic
site
countri
worldwid
influenza
season
patient
eventu
random
studi
termin
futil
plan
interim
analysi
sampl
size
requir
maintain
power
exceed
predefin
boundari
base
practic
consider
feasibl
total
sampl
size
iv
zanamivir
also
recent
fail
show
superior
oral
oseltamivir
one
largest
random
doubleblind
clinic
trial
conduct
nai
marti
et
al
current
regulatori
guidanc
support
noninferior
studi
design
given
recommend
nai
use
hospit
patient
despit
lack
definit
prospect
rct
popul
us
food
drug
administr
unfortun
unclear
whether
superior
demonstr
compar
two
separ
nai
drug
addit
studi
hospit
patient
hamper
lack
previous
valid
endpoint
highrisk
popul
potenti
consider
supplement
current
clinic
virolog
endpoint
would
use
score
royal
colleg
physician
ordin
scale
peterson
et
al
futur
prospect
studi
interdisciplinari
effort
advanc
ordin
scale
combin
endpoint
need
prabha
viswanathan
fda
silver
spring
md
usa
rsvassoci
ill
rsvai
signific
public
health
impact
unit
state
worldwid
rsv
well
known
lead
caus
lrti
infant
young
children
hall
et
al
shi
et
al
rsv
also
caus
sever
diseas
popul
includ
older
adult
falsey
et
al
shi
et
al
individu
chronic
lung
cardiac
diseas
immunocompromis
patient
although
therapeut
option
current
limit
sever
product
develop
treatment
prevent
rsvai
nicholson
munoz
mani
target
viral
fusion
genom
replic
fda
publish
guidanc
industri
assist
sponsor
clinic
develop
drug
treatment
prevent
diseas
caus
rsv
us
food
drug
administr
although
guidanc
focus
primarili
develop
drug
rsv
infant
children
special
popul
also
given
attent
new
drug
treatment
prevent
demonstr
broad
antivir
activ
divers
rsv
strain
sponsor
monitor
emerg
amino
acid
substitut
may
confer
resist
random
doubleblind
compar
trial
conduct
treatment
prevent
product
optim
endpoint
establish
treatment
trial
phase
studi
evalu
combin
clinic
virolog
endpoint
phase
trial
endpoint
reflect
improv
clinic
sign
symptom
rsvassoci
ill
feel
function
surviv
prevent
trial
fda
prefer
endpoint
laboratoryconfirm
medic
attend
lrti
order
facilit
develop
novel
drug
collabor
effort
need
develop
definit
diseas
sever
establish
consensu
definit
lrti
develop
reliabl
instrument
measur
clinic
improv
john
devincenzo
univers
tennesse
memphi
tn
usa
past
decad
great
stride
made
develop
potenti
effect
rsv
antivir
rsv
diseas
sever
first
correl
viral
load
furthermor
signific
correl
initi
viral
load
upper
lower
airway
intub
children
found
perkin
et
al
faster
rsv
clearanc
independ
associ
shorter
hospit
el
saleebi
et
al
low
passag
live
clinic
cgmp
grade
rsv
viru
known
memphi
rsv
gener
use
human
challeng
studi
kim
et
al
challeng
model
healthi
adult
demonstr
parallel
natur
viral
kinet
diseas
kinet
within
human
model
system
devincenzo
et
al
aerosol
ribavirin
first
market
treatment
rsv
children
date
still
convinc
evid
clinic
benefit
antivir
effect
human
popul
special
popul
includ
immunocompromis
beaird
et
al
often
deliv
oral
iv
form
gener
drug
concentr
site
rsv
replic
far
lower
need
inhibit
viral
replic
sever
potent
select
small
molecul
antivir
compound
identifi
progress
clinic
trial
novel
rsv
fusion
inhibitor
may
produc
superior
clinic
effect
compar
ribavirin
natur
rsv
infect
anoth
fusion
inhibitor
shown
decreas
viral
load
sever
clinic
diseas
lumicitabin
oral
nucleosid
analog
demonstr
proof
concept
human
rsv
challeng
model
devincenzo
et
al
final
nonnucleosid
l
protein
polymeras
inhibitor
undergon
preclin
character
coat
et
al
antivir
also
clinic
develop
includ
repres
fusion
inhibitor
class
replic
inhibitor
class
understand
rsv
replic
kinet
individu
atrisk
popul
well
viru
dynam
upper
lower
respiratori
tract
diseas
need
adroitli
design
clinic
trial
evalu
efficaci
antivir
clinic
set
mer
caus
novel
human
coronaviru
merscov
thought
transmit
human
via
close
contact
camel
six
year
sinc
identif
merscov
document
case
mer
human
mortal
rate
report
countri
merscov
case
occur
kingdom
saudi
arabia
spectrum
diseas
vari
asymptomat
identifi
contact
trace
sever
ill
character
hypoxem
respiratori
failur
eventu
multiorgan
failur
result
mortal
critic
ill
patient
reach
arabi
et
al
one
post
mortem
analysi
reveal
merscov
infect
patient
lung
detect
necrot
pneumonia
diffus
alveolar
damag
addit
acut
kidney
liver
damag
myositi
viru
identifi
case
electron
microscopi
lung
kidney
muscl
higher
level
interferon
merscov
specif
antibodi
link
better
outcom
compar
patient
lower
level
treatment
patient
mer
proven
challeng
specif
antivir
therapi
proven
efficaci
avail
date
one
multicent
cohort
studi
adjust
timevari
confound
corticosteroid
treatment
merscov
infect
patient
significantli
associ
differ
mortal
rate
associ
delay
merscov
rna
clearanc
arabi
et
al
treatment
convalesc
plasma
promis
like
feasibl
given
limit
pool
potenti
donor
one
studi
show
even
recov
patient
mer
suffici
antibodi
titer
therapeut
use
arabi
et
al
arabi
et
al
ribavirin
interferon
treatment
produc
promis
preclin
data
rhesu
macaqu
includ
moder
reduct
viral
load
partial
effect
prevent
progress
pneumonia
infect
anim
compar
untreat
infect
control
falzarano
et
al
howev
data
merscov
infect
patient
treat
combin
ribavirin
interferon
either
inconsist
depend
statist
analysi
method
use
compar
dataset
al
ghamdi
et
al
altawfiq
et
al
omrani
et
al
shalhoub
et
al
largest
studi
adjust
timevari
confound
might
influenc
decis
initi
ribavirin
interferon
therapi
show
improv
mortal
arabi
et
al
furthermor
dose
ribavirin
requir
reduc
merscov
replic
often
associ
signific
toxic
human
hart
et
al
interferon
test
interferon
effect
merscov
vitro
dose
lower
clinic
treatment
regimen
hart
et
al
human
immunodefici
viru
proteas
inhibitor
lopinavirritonavir
plu
interferon
treatment
shown
effect
sarscov
infect
patient
also
reduc
weight
loss
clinic
score
viral
titer
diseas
progress
merscov
infect
marmoset
chan
et
al
chu
et
al
de
wild
et
al
lopinavirritonavir
plu
interferon
treatment
evalu
miracl
trial
merscov
infect
patient
current
recruit
patient
site
arabi
et
al
differ
monoclon
polyclon
antibodi
treatment
merscov
develop
undergo
clinic
evalu
includ
antibodi
gener
transchromosom
cattl
luke
et
al
gilead
scienc
nucleotid
analog
prodrug
remdesivir
broad
spectrum
antivir
activ
filovirus
paramyxovirus
highli
pathogen
human
coronavirus
remdesivir
prophylact
therapeut
effect
sarsand
merscov
multipl
anim
model
sheahan
et
al
pharmacokinet
studi
alreadi
complet
clinic
trial
underway
remdesivir
treat
ebola
viru
futur
studi
focu
increas
number
site
merscov
clinic
trial
conduct
recruit
patient
trial
earlier
infect
time
cours
possibl
mobil
respons
team
recruit
patient
anywher
saudi
arabia
final
addit
studi
evalu
benefit
combin
therapi
perform
hope
find
way
reduc
viral
replic
strengthen
immun
respons
reduc
diseas
burden
follow
merscov
infect
simon
portsmouth
shionogi
inc
florham
park
nj
usa
result
present
studi
intern
random
doubleblind
control
treatment
studi
patient
age
year
higher
risk
influenza
complic
defin
cdc
criteria
particip
influenza
b
present
within
h
onset
influenza
symptom
elig
particip
particip
random
receiv
singl
oral
dose
baloxavir
oseltamivir
placebo
day
primari
endpoint
time
clinic
improv
defin
time
symptom
judg
mild
absent
random
pt
compris
infect
itt
popul
baloxavir
arm
placebo
oseltamivir
virus
isol
mainli
influenza
influenza
b
influenza
common
risk
factor
asthma
chronic
lung
diseas
age
year
time
improv
influenza
symptom
shorter
treat
baloxavir
compar
placebo
median
h
vs
h
p
similar
oseltamivir
h
p
median
time
cessat
viral
shed
baloxavir
h
compar
h
receiv
either
placebo
oseltamivir
complic
less
frequent
receiv
baloxavir
compar
placebo
vs
primarili
bronchiti
incid
advers
event
seriou
advers
event
differ
significantli
across
group
pair
sampl
baselin
post
treatment
incid
substitut
overal
sampl
influenza
influenza
influenza
b
appear
relat
increas
symptom
baloxavir
well
toler
associ
faster
recoveri
reduc
risk
complic
high
risk
influenza
patient
compar
placebo
david
oldach
visterra
inc
waltham
usa
monoclon
antibodi
engin
target
known
strain
influenza
includ
season
influenza
emerg
strain
influenza
tharakaraman
et
al
studi
phase
random
doubleblind
trial
evalu
singledos
iv
administ
mg
mg
compar
placebo
particip
year
age
influenza
hershberg
et
al
particip
random
receiv
studi
drug
confirm
influenza
influenza
subject
receiv
singl
dose
diphenhydramin
plu
ibuprofen
acetylsalicyl
acid
h
prior
studi
drug
administr
primari
object
studi
determin
safeti
toler
advers
event
commonli
diarrhea
mild
sever
doserel
occur
mg
mg
placebo
patient
respect
two
seriou
advers
event
occur
placebo
patient
symptom
assess
flu
pro
power
et
al
resolut
defin
mean
score
domain
vi
mg
cohort
nonstatist
shorter
time
resolut
compar
placebo
though
mg
cohort
similar
placebo
post
hoc
analysi
demonstr
mean
total
flupro
score
lower
day
pool
treatment
group
versu
placebo
p
tendenc
toward
faster
resolut
kaplanmei
analysi
associ
reduc
median
nasopharyng
viral
load
tissu
cultur
infect
dose
tcid
area
curv
auc
day
day
log
tcid
ml
pool
vs
placebo
p
among
patient
posit
cultur
baselin
cultur
neg
day
observ
pool
recipi
versu
placebo
recipi
p
kaplanmei
estim
time
resolut
viral
shed
reduc
vs
day
p
profil
viral
rna
shed
detect
qpcr
differ
treatment
arm
evid
treatmentemerg
observ
base
genotyp
assess
viral
isol
ha
target
epitop
found
highli
conserv
combin
small
molecul
antivir
may
clinic
benefit
result
studi
support
proceed
phase
trial
combin
oseltamivir
vs
oseltamivir
alon
hospit
patient
influenza
clinicaltrialsgov
identifi
bin
cao
china
japan
friendship
hospit
beij
china
favipiravir
novel
polymeras
inhibitor
activ
influenza
mani
virus
furuta
et
al
pharmacokinet
favipiravir
critic
ill
patient
influenza
unknown
open
label
adapt
studi
evalu
pharmacokinet
favipiravir
adult
patient
sever
influenza
defin
pao
fio
mmhg
orand
requir
mechan
ventil
primari
endpoint
proport
patient
plasma
favipiravir
trough
concentr
mec
measur
time
point
second
dose
total
laboratoryconfirm
influenzainfect
particip
enrol
trial
first
dose
mg
bid
day
follow
mg
bid
day
predict
favipiravir
concentr
day
ml
day
observ
concentr
significantli
less
day
median
valu
day
patient
trough
concentr
concentr
oseltamivir
remain
stabl
possibl
reason
lower
favipiravir
level
includ
poor
absorpt
redistribut
increas
metabol
addit
studi
need
conduct
understand
dose
favipiravir
critic
ill
popul
stephen
toovey
ark
bioscienc
shanghai
china
current
effect
antivir
treatment
rsv
infect
infant
ziresovir
fusion
inhibitor
activ
rsv
b
ec
nanomolar
concentr
drug
resist
clinic
isol
mckimmbreschkin
et
al
current
victor
studi
random
doubleblind
placebocontrol
phase
trial
children
month
hospit
rsv
result
singl
dose
part
report
dose
escal
studi
dose
mgkg
studi
primari
object
safeti
toler
sae
report
ae
report
patient
ae
thought
dose
relat
dose
depend
decreas
symptom
score
h
singl
dose
ziresovir
patient
receiv
ziresovir
deterior
contrast
placebo
group
earli
result
suggest
ziresovir
clinic
efficaci
rsv
would
first
antivir
shown
clinic
benefit
infant
natur
acquir
rsv
diseas
encourag
result
support
continu
phase
trial
multidos
cohort
current
ongo
umifenovir
arbidol
indolederiv
molecul
licens
russia
china
prophylaxi
treatment
influenza
respiratori
viral
infect
blais
et
al
umifenovir
interact
viral
ha
inhibit
ha
function
kadam
wilson
activ
influenza
b
virus
includ
influenza
oseltamivir
resist
virus
leneva
et
al
zeng
et
al
first
studi
report
evalu
mous
model
secondari
aureu
pneumonia
pneumonia
follow
influenza
infect
mice
treat
umifenovir
mgkg
mgkg
oseltamivir
mgkg
placebo
oral
treatment
umifenovir
oseltamivir
improv
surviv
mice
increas
time
death
decreas
weight
loss
compar
placebo
umifenovir
oseltamivir
also
reduc
viru
titer
log
decreas
bacteri
coloni
count
lung
show
less
sever
histopatholog
find
mous
lung
compar
control
group
second
studi
report
retrospect
observ
studi
includ
patient
admit
hospit
region
russia
acut
respiratori
viral
infect
data
collect
routin
medic
record
patient
includ
demograph
clinic
observ
includ
chronic
medic
condit
treatment
given
laboratori
test
result
follow
chest
xray
pneumonia
develop
patient
treat
umifenovir
within
h
patient
treat
within
h
treat
umifenovir
earli
treatment
umifenovir
may
decreas
incid
pneumonia
among
hospit
highrisk
popul
multipl
issu
relat
clinic
trial
regulatori
issu
regard
influenza
respiratori
viral
research
discuss
roundtabl
discuss
gap
research
influenza
well
respiratori
virus
rsv
address
difficulti
design
clinic
trial
new
therapeut
special
popul
discuss
well
need
obtain
reliabl
concomit
data
emerg
resist
pattern
final
need
standard
welldefin
endpoint
also
examin
prior
fda
approv
baloxavir
viabl
therapeut
option
avail
treatment
influenza
limit
nai
despit
widespread
use
pauciti
trial
util
nai
hospit
critic
ill
immunocompromis
patient
occasion
nonfda
approv
treatment
option
iv
zanamivir
releas
compassion
use
understudi
popul
shah
et
al
outcom
data
alway
adequ
report
back
pharmaceut
compani
fda
even
mortal
morbid
outcom
avail
data
could
potenti
suffer
select
bia
given
usual
administ
critic
ill
frequent
moribund
patient
need
obtain
outcom
data
patient
receiv
drug
releas
compassion
use
via
standard
data
sheet
electron
databas
discuss
clear
end
goal
mani
antivir
increas
proport
influenzainfect
patient
treat
within
time
fashion
ison
mani
influenzarel
studi
encount
difficulti
enrol
patient
due
delay
present
research
requir
understand
driver
influenzainfect
patient
seek
care
abil
access
care
time
fashion
strategi
util
outpati
network
previous
creat
vaccin
trial
suggest
rapid
organ
monitor
influenza
resist
pattern
remain
challeng
especi
within
hospit
immunocompromis
patient
one
strategi
obtain
adequ
inform
resist
pattern
would
includ
mandat
ongo
monitor
resist
pattern
within
popul
clinic
trial
exampl
global
resist
profil
monitor
network
short
period
incid
studi
sever
acut
respiratori
infect
sprintsari
intern
multicentr
prospect
short
period
incid
observ
studi
patient
particip
hospit
icu
establish
respond
futur
epidemicpandem
appropri
endpoint
respiratori
virus
hospit
immunocompromis
patient
also
discuss
propos
endpoint
may
consid
includ
ordin
scale
conjunct
microbiolog
data
immunomodul
may
requir
differ
endpoint
antivir
moreov
signific
heterogen
even
within
hospit
popul
wide
variat
underli
condit
immunosuppress
mani
studi
util
ordin
scale
need
conduct
heterogen
popul
respiratori
virus
certain
endpoint
standard
across
studi
sinc
baloxavir
approv
use
influenza
trial
combin
therapi
consid
patient
risk
increas
resist
global
consider
given
vulner
popul
middleincom
countri
face
increas
chronic
comorbid
condit
collabor
effort
policymak
necessari
order
creat
network
allow
monitor
global
resist
pattern
aeron
hurt
collabor
centr
melbourn
australia
addit
endonucleas
inhibitor
baloxavir
marboxil
three
class
directact
antivir
approv
treatment
influenza
viru
new
rna
polymeras
inhibitor
class
nai
adamantan
emerg
virus
reduc
suscept
commonli
refer
antivir
resist
either
within
treat
patient
circul
host
observ
three
drug
class
bright
et
al
gubareva
et
al
omoto
et
al
surveil
drug
resist
must
global
continu
tempor
geograph
restrict
sampl
inadequ
identifi
trend
may
impact
treatment
option
adamantan
resist
emerg
among
season
virus
rose
frequenc
pandem
viru
adamantaneresist
emerg
human
adamantanesensit
virus
circul
low
frequenc
ever
sinc
peak
influenza
season
australia
howev
adamantanesensit
virus
detect
indic
local
increas
revers
wildtyp
global
frequenc
remain
convers
oseltamivirresist
virus
histor
circul
low
frequenc
rose
nearli
global
prior
replac
oseltamivirsensit
pandem
viru
baranovich
et
al
center
diseas
prevent
incid
circul
variant
reduc
suscept
baloxavir
current
low
gubareva
et
al
although
treatmentemerg
resist
report
approxim
clinic
trial
particip
depend
age
potenti
factor
takashita
et
al
xofluza
increas
rate
detect
resist
viru
untreat
patient
could
indic
transmiss
resist
variant
increas
fit
thu
continu
monitor
requir
risk
emerg
circul
resist
may
inform
featur
treatmentemerg
resist
year
resist
monitor
studi
includ
longitudin
sampl
oseltamivirtr
patient
infect
influenza
viru
rate
treatmentemerg
resist
nearli
higher
children
year
age
higher
overal
among
infect
patient
agerel
trend
observ
recent
publish
result
baloxavir
marboxil
treatmentemerg
resist
pediatr
patient
year
age
takashita
et
al
compar
approxim
overal
patient
year
age
xofluza
treatmentemerg
resist
even
common
immunosuppress
patient
shed
viru
longer
period
memoli
et
al
resist
variant
detect
use
phenotyp
assay
determin
effect
inhibitori
concentr
drug
viru
growth
ec
enzymat
activ
ic
target
eg
na
pa
use
genotyp
assay
detect
known
genet
chang
associ
reduc
suscept
phenotyp
nai
assay
wellcharacter
requir
cultiv
isol
make
inadequ
pointofcar
diagnost
gener
less
sensit
detect
resist
variant
mix
popul
wetheral
et
al
howev
newer
technolog
attempt
reduc
turnaround
time
increas
sensit
standard
nai
assay
gubareva
et
al
lack
standard
clear
relationship
level
reduc
suscept
clinic
outcom
make
phenotyp
assay
difficult
interpret
also
continu
area
studi
genotyp
assay
gener
rapid
sensit
requir
prior
knowledg
effect
certain
mutat
viru
suscept
genotyp
assay
vari
scope
realtim
pcr
snp
detect
sanger
nextgener
sequenc
whole
gene
genom
advent
influenza
antivir
distinct
mechan
action
requir
new
assay
approach
phenotyp
assay
baloxavir
current
neither
rapid
highthroughput
although
advanc
current
made
genet
determin
reduc
suscept
baloxavir
still
defin
class
drug
surveil
involv
use
genotyp
phenotyp
assay
account
emerg
spread
resist
rubaiyea
farruke
collabor
centr
refer
research
influenza
vidrl
univers
melbourn
australia
observ
studi
treatment
respons
oseltamivir
patient
infect
viru
reduc
vitro
suscept
oseltamivir
confer
na
patient
infect
sensit
wildtyp
indic
relationship
vitro
suscept
clinic
outcom
kawai
et
al
howev
relationship
level
suscept
inhibitori
concentr
drug
ic
valu
influenza
viru
measur
nai
assay
clinic
effect
treatment
remain
illdefin
better
understand
relationship
model
system
impact
oseltamivir
treatment
evalu
ferret
infect
influenza
type
b
virus
without
resistanceassoci
na
substitut
repres
rang
suscept
ic
valu
oseltamivir
na
inhibit
assay
ferret
use
model
infect
humanderiv
influenza
viru
strain
contact
inocul
donor
ferret
show
sign
diseas
similar
human
includ
fever
group
ferret
dose
mgkg
oseltamivir
placebo
h
prior
infect
contact
donor
ferret
infect
pandem
lineag
viru
pdm
ic
nm
lineag
ic
nm
ic
nm
type
b
viru
ic
nm
variant
repres
viru
typesubtyp
na
substitut
reduc
suscept
oseltamivir
ic
rang
nm
treatment
continu
twice
daili
day
antivir
activ
oseltamivir
assess
base
viru
shed
area
curv
auc
reduct
rel
placebo
oseltamivir
treatment
least
effect
type
b
viru
infect
exhibit
ic
greater
type
virus
among
type
virus
vari
approxim
ic
valu
clear
associ
viru
shed
reduct
ic
valu
demonstr
antivir
effect
oseltamivir
compar
placebo
ferret
infect
virus
na
resist
substitut
ic
valu
rang
nm
base
linear
regress
model
relationship
infect
viru
ic
valu
viru
shed
auc
ferret
ic
valu
nm
nm
associ
reduct
oseltamivir
effect
respect
larg
differ
suscept
virus
nai
assay
may
predict
impact
oseltamivir
treatment
viru
shed
differ
relat
clinic
outcom
human
whether
smaller
differ
suscept
may
predict
treatment
respons
requir
addit
investig
pa
endonucleas
inhibitor
new
class
antivir
influenza
viru
act
inhibit
abil
viru
prime
viral
gene
transcript
use
g
capcontain
oligom
cleav
host
mrna
endonucleas
activ
pa
member
influenza
viru
polymeras
complex
dia
et
al
baloxavir
marboxil
first
pa
inhibitor
approv
treatment
influenza
viru
infect
firstgener
pa
inhibitor
includ
diketo
acid
structur
act
chelat
bival
cation
within
pa
activ
site
inhibitor
low
affin
micromolar
rang
low
select
indic
ju
et
al
stevaert
et
al
baloxavir
acid
activ
form
baloxavir
marboxil
structur
similar
jone
et
al
improv
origin
concept
maintain
diketo
acidlik
motif
fuse
ring
structur
increas
select
affin
nanomolar
rang
pa
endonucleas
activ
site
jone
et
al
noshi
et
al
order
defin
pathway
resist
nextgener
pa
endonucleas
inhibitor
better
character
molecular
basi
inhibit
resist
humanderiv
laboratoryadapt
strain
influenza
virus
puerto
serial
passag
cell
cultur
increas
concentr
select
virus
reduc
suscept
virus
appar
reduc
suscept
observ
passag
viru
recov
passag
exhibit
increas
ec
valu
nm
nm
resist
phenotyp
maintain
addit
passag
absenc
select
pressur
indic
fit
cost
reduc
suscept
may
limit
sequenc
pa
reveal
singl
amino
acid
substitut
also
select
baloxavir
acid
cell
cultur
byrn
et
al
date
frequent
observ
treatmentemerg
resist
substitut
baloxavir
marboxiltr
patient
cocrystal
pa
ntermin
region
contain
endonucleas
domain
reveal
disrupt
strong
hydrophob
interact
bind
pocket
isotherm
calorimetri
pa
protein
presenc
reveal
nearli
reduct
k
bind
pa
nm
associ
substitut
impact
substitut
enzymat
function
replic
capac
cell
cultur
evalu
determin
scope
pathway
resist
substitut
potenti
fit
cost
screen
potenti
amino
acid
substitut
posit
context
complet
polymeras
complex
use
minireplicon
system
reveal
substitut
result
reduc
endonucleas
activ
reduc
activ
least
nonetheless
wild
type
viru
grew
higher
titer
multistep
growth
assay
outcompet
mutant
viru
competit
assay
result
consist
result
similar
experi
carri
baloxavir
indic
resist
pa
inhibitor
come
fit
cost
howev
potenti
addit
substitut
compens
cost
yet
explor
emi
takashita
nation
institut
infecti
diseas
tokyo
japan
baloxavir
marboxil
pa
endonucleas
inhibitor
recent
approv
japan
us
treatment
influenza
viru
infect
treatmentemerg
resist
observ
adolesc
adult
clinic
studi
omoto
et
al
xofluza
among
pa
amino
acid
substitut
shown
reduc
suscept
baloxavir
identifi
viru
treat
patient
common
date
circul
viru
substitut
known
reduc
suscept
baloxavir
current
rare
rapid
robust
assay
need
activ
surveil
viru
reduc
suscept
baloxavir
plaqu
assay
well
character
robust
depend
visual
cytopath
effect
viru
spread
among
neighbor
cell
requir
sever
day
incub
plaqu
form
larg
enough
visual
addit
virus
highli
cytopath
focusform
assay
spread
viru
singl
infect
cell
neighbor
cell
detect
immunofluoresc
stain
autom
microscop
imag
detect
foci
requir
long
incub
period
depend
cytopathogen
viru
highthroughput
focusform
assay
compar
plaqu
assay
abil
detect
reduc
suscept
baloxavir
acid
activ
form
baloxavir
marboxil
among
refer
strain
refer
strain
includ
virus
without
substitut
confer
reduct
suscept
baloxavir
assay
consist
fold
chang
observ
substitut
studi
jone
et
al
omoto
et
al
panel
nairesist
virus
sensit
counterpart
also
evalu
suscept
assay
show
similar
result
valid
focusform
assay
adequ
surveil
tool
virus
isol
commun
influenza
season
japan
bvictorialineag
byamagatalineag
evalu
suscept
focusform
assay
focusform
assay
median
baloxavir
ec
valu
influenza
type
type
b
commun
isol
nm
respect
rang
approxim
median
clear
outlier
indic
significantli
reduc
suscept
virus
express
wildtyp
pa
howev
limit
variat
ec
valu
observ
could
driven
viral
genet
determin
baloxavir
exhibit
wildtyp
ec
valu
refer
strain
known
nai
resist
substitut
consist
distinct
mechan
action
baloxavir
nationwid
surveil
virus
reduc
suscept
baloxavir
japan
implement
use
highthroughput
focu
form
assay
larisa
gubareva
cdc
atlanta
ga
usa
world
health
organ
global
influenza
surveil
respons
system
gisr
collabor
centr
influenza
divis
us
cdc
monitor
suscept
circul
influenza
virus
antivir
approv
market
late
stage
clinic
develop
influenza
rnadepend
rna
polymeras
three
heterolog
subunit
pa
repres
attract
target
antivir
develop
baloxavir
marboxil
recent
approv
japan
us
antivir
inhibit
pa
endonucleas
activ
influenza
b
virus
pimodivir
latestag
develop
specif
target
g
capbind
activ
influenza
virus
select
studi
cell
cultur
analysi
virus
drugtreat
patient
clinic
trial
reveal
princip
pathway
reduc
suscept
baloxavir
jone
et
al
omoto
et
al
pimodivir
byrn
et
al
trevejo
et
al
baloxavir
studi
treatmentemerg
amino
acid
substitut
frequent
occur
conserv
posit
f
mt
pa
endonucleas
activ
site
confer
reduc
suscept
influenza
influenza
b
substitut
posit
capbind
site
recogn
lead
pathway
reduc
suscept
pimodivir
next
gener
sequenc
ng
analysi
influenza
type
b
virus
collect
us
show
three
virus
abovement
substitut
howev
drugresist
influenza
virus
becom
transmiss
spread
wide
essenti
monitor
drug
suscept
among
season
nonseason
influenza
virus
routin
virolog
surveil
carri
ng
analysi
monitor
known
determin
reduc
drug
suscept
empir
assess
phenotyp
drug
suscept
assay
cell
culturebas
assay
slow
cumbersom
requir
multipl
round
viru
replic
facilit
surveil
effort
cdc
laboratori
develop
singlecycl
assay
highcont
imagingbas
neutral
test
hint
assay
cell
infect
influenza
viru
absenc
trypsin
limit
viru
spread
h
incub
cell
fix
immunofluoresc
stain
antinp
antibodi
imag
use
autom
fluoresc
cell
counter
baloxavir
ec
valu
measur
use
hint
assay
within
approxim
valu
obtain
focu
reduct
plaqu
reduct
assay
hint
assay
reveal
substitut
detect
two
virus
yet
uncharacter
confer
reduct
baloxavir
suscept
compar
reduct
observ
previous
character
treatmentemerg
substitut
pimodivir
hint
ec
valu
higher
ec
valu
determin
focu
reduct
assay
nevertheless
fold
chang
confer
substitut
remain
consist
two
assay
hint
assay
provid
higher
throughput
option
phenotyp
surveil
season
low
pathogen
influenza
virus
hint
work
highli
pathogen
avian
influenza
virus
hint
assay
yet
avail
influenza
c
virus
suscept
baloxavir
assess
use
viru
yield
reduct
assay
baloxavir
potent
inhibit
replic
virus
test
show
highest
activ
type
lowest
influenza
virus
panel
discuss
futur
challeng
resist
monitor
moder
maria
zambon
discuss
focus
remain
question
regard
resist
baloxavir
scope
techniqu
use
surveil
effort
potenti
use
combin
therapi
mitig
treatmentemerg
resist
one
question
rais
whether
certain
genet
background
may
associ
substitut
reduc
suscept
baloxavir
substitut
reduc
suscept
baloxavir
shown
reduc
replic
capac
cell
cultur
certain
genet
background
compensatori
substitut
may
increas
replic
fit
vivo
transmiss
resist
virus
determin
yet
identifi
although
rate
treatmentemerg
substitut
far
higher
type
influenza
viru
compar
type
b
influenza
viru
clear
differ
rate
influenza
viru
type
driven
primarili
reduc
activ
baloxavir
type
b
viru
greater
fit
cost
resist
type
b
viru
scope
method
use
baloxavir
resist
surveil
current
work
among
agenc
across
globe
far
amino
acid
posit
pa
list
uspi
determin
baloxavir
resist
addit
work
ongo
describ
impact
substitut
observ
report
sequenc
site
gubareva
et
al
one
import
open
question
whether
identifi
correl
level
resist
measur
certain
phenotyp
assay
clinic
outcom
treat
patient
substanti
proport
subject
clinic
trial
baloxavir
exhibit
treatmentemerg
resist
highest
rate
observ
pediatr
trial
takashita
et
al
treatmentemerg
resist
associ
reduc
clinic
respons
treatment
prolong
viru
shed
observ
rais
possibl
baloxavir
marboxil
may
effect
use
combin
anoth
antivir
ie
nai
may
enhanc
overal
effect
also
mitig
risk
select
transmiss
resist
virus
could
end
wide
circul
fate
adamantan
hot
topic
latebreak
antivir
design
emerg
preepidem
coronavirus
ralph
baric
univers
north
carolina
chapel
hill
nc
usa
virus
emerg
zoonot
reservoir
present
uniqu
challeng
develop
treatment
andor
vaccin
strategi
prepar
requir
readi
combat
virus
yet
identifi
highli
pathogen
human
coronavirus
sarscov
merscov
origin
bat
zoonot
reservoir
pass
differ
intermedi
host
prior
infect
human
bat
coronaviru
strain
share
vari
homolog
mersand
sarscov
still
circul
repres
preepidem
strain
like
make
jump
human
anthoni
et
al
becker
et
al
menacheri
et
al
menacheri
et
al
sheahan
et
al
sheahan
et
al
mani
novel
bat
coronaviru
strain
identifi
sole
genom
sequenc
isol
bat
guano
character
strain
beyond
sequenc
analysi
initi
possibl
determin
sarscovlik
bat
coronavirus
could
replic
use
nonhuman
primat
human
cellular
attach
protein
baric
laboratori
clone
individu
bat
coronaviru
spike
gene
sarscov
infecti
clone
backbon
isol
replic
compet
virus
sarscovbatcov
spike
virus
evalu
cell
line
express
either
human
bat
civet
angiotensin
convert
enzym
cellular
receptor
determin
host
speci
specif
identifi
candid
batcov
strain
gener
infecti
clone
base
entir
bat
coronaviru
genom
four
six
sarscovbatcov
spike
virus
test
could
use
three
molecul
entri
replic
high
titer
plaqu
form
unitsml
becker
et
al
menacheri
et
al
rockx
et
al
four
bat
coronaviru
strain
isol
infecti
clone
deriv
respect
genom
result
viru
progeni
use
character
replic
kinet
immort
cell
line
primari
human
lung
cell
cultur
perform
vivo
vaccin
treatment
experi
comparison
wild
type
sarscov
replic
high
titer
titer
wild
type
sarscov
primari
lung
cell
cultur
suggest
strain
fulli
compet
infect
human
murin
diseas
model
highli
pathogen
human
coronaviru
infect
bat
coronaviru
strain
attenu
comparison
wild
type
mous
adapt
sarscov
vaccin
studi
demonstr
vaccin
specif
sarscov
effect
bat
coronaviru
strain
antibodi
treatment
protect
sarscov
fail
bat
strain
becker
et
al
menacheri
et
al
rockx
et
al
rockx
et
al
data
highlight
crucial
evalu
treatment
option
current
past
human
strain
sarsand
merscov
appropri
treatment
vaccin
strategi
stock
pile
prepar
futur
epidem
previou
studi
shown
remdesivir
formerli
broad
spectrum
antivir
activ
vivo
efficaci
filovirus
paramyxovirus
coronavirus
includ
merscov
siegel
et
al
warren
et
al
remdesivir
pharmacokinet
studi
complet
compound
current
evalu
clinic
trial
ebola
viru
efficaci
nucleotidesid
analogu
includ
remdesivir
test
determin
effect
highli
pathogen
human
coronavirus
despit
previou
studi
demonstr
nucleotid
analogu
gener
poor
activ
coronavirus
due
proofread
enzym
part
viral
replic
machineri
studi
human
lung
cell
line
primari
human
lung
epitheli
cell
cultur
demonstr
remdesivir
effect
sarsand
merscov
well
preepidem
batcov
strain
describ
earlier
sheahan
et
al
parallel
vitro
passag
studi
also
perform
determin
coronaviru
genom
could
evolv
replic
presenc
remdesivir
passag
presenc
drug
two
mutat
identifi
viral
rna
depend
rna
polymeras
gene
allow
increas
replic
presenc
remdesivir
agostini
et
al
two
amino
acid
chang
decreas
viral
fit
overal
attenu
sarscov
pathogenesi
mous
model
sarscov
induc
diseas
agostini
et
al
prophylact
therapeut
h
post
infect
dose
regimen
sarscov
infect
anim
remdesivir
treat
anim
log
reduct
viral
titer
day
post
infect
sheahan
et
al
remdesivir
treat
anim
also
maintain
start
weight
throughout
infect
time
cours
vehicl
treat
anim
lost
start
weight
day
post
infect
sheahan
et
al
final
improv
lung
function
less
airway
constrict
reduc
time
breath
seen
treat
anim
compar
sarscov
infect
untreat
control
anim
sheahan
et
al
similar
result
seen
merscov
prophylact
dose
studi
perform
baric
laboratori
merscov
mous
model
cockrel
et
al
contrast
therapeut
treatment
human
monoclon
antibodi
protect
merscov
induc
sever
diseas
protect
loss
lung
function
anim
model
highli
pathogen
human
coronaviru
diseas
cockrel
et
al
remdesivir
promis
broadspectrum
antivir
may
prove
use
treatment
highli
pathogen
human
coronaviru
remdesivir
provid
superior
therapeut
efficaci
lopinavir
ritonavir
interferon
beta
merscov
ami
sim
univers
north
carolina
chapel
hill
nc
usa
current
us
fda
approv
therapeut
treat
sarscov
merscov
infect
wide
rang
compound
evalu
activ
highli
pathogen
human
coronavirus
includ
biolog
small
molecul
among
nucleotid
analog
remdesivir
show
potent
activ
coronavirus
review
baric
arabi
summari
remdesivir
current
evalu
random
clinic
trial
treatment
patient
ebola
viru
diseas
combin
lopinavir
ritonavir
fda
approv
antivir
treatment
human
immunodefici
viru
hiv
infect
croxtal
perri
perri
et
al
previou
studi
antivir
activ
lopinavir
merscov
conflict
one
studi
report
micromolar
ec
valu
human
hepatoma
cell
line
huh
yet
anoth
report
lopinavir
activ
nonhuman
primat
kidney
cell
line
vero
de
wild
et
al
type
interferon
approv
treat
multipl
indic
includ
hepat
b
c
multipl
sclerosi
dumitrescu
et
al
li
et
al
two
studi
show
interferonbeta
effect
merscov
infect
nonhuman
primat
kidney
cell
vero
ec
valu
iuml
hart
et
al
clinic
observ
vivo
anim
model
indic
outcom
merscov
infect
mediat
viru
replic
result
host
inflammatori
respons
combin
therapi
directli
target
viru
host
may
repres
best
cours
treatment
highli
pathogen
human
coronavirus
cocktail
lopinavirritonavir
plu
interferonbeta
current
evalu
patient
infect
merscov
miracl
trial
arabi
et
al
purpos
studi
describ
compar
antivir
activ
remdesivir
lopinavir
ritonavir
interferonbeta
merscov
infect
mockinfect
human
lung
epitheli
cell
calu
treat
dilut
seri
lopinavir
ritonavir
interferonbeta
iuml
iuml
remdesivir
result
assay
h
post
infect
cytotox
evalu
noninfect
cell
ec
valu
determin
drug
lopinavir
ritonavir
demonstr
moder
minim
inhibit
viru
replic
respect
ec
valu
interferonbeta
treatment
merscov
infect
human
lung
epitheli
cell
inhibit
viral
replic
similar
previou
studi
nonhuman
primat
kidney
cell
vero
hart
et
al
howev
ec
valu
studi
higher
iuml
human
lung
cell
iuml
nonhuman
primat
kidney
cell
contrast
remdesivir
potent
inhibit
merscov
replic
submicromolar
ec
sheahan
et
al
facilit
vivo
efficaci
studi
merscov
rodent
mous
model
gener
human
murin
ortholog
human
receptor
dipeptidyl
peptidas
cockrel
et
al
conjunct
genet
delet
carboxyl
esteras
minim
rodent
serum
esterasespecif
remdesivir
degrad
sheahan
et
al
dosag
combin
lopinavir
mgkg
qd
ritonavir
mgkg
qd
base
human
equival
dose
use
bodi
surfac
area
mous
recombin
interferonbeta
dose
two
concentr
iu
kg
qd
cover
human
equival
dose
respect
dosag
remdesivir
mgkg
bid
chosen
base
pharmacokinet
studi
perform
mice
sheahan
et
al
treatment
initi
one
day
post
infect
dpi
mous
adapt
merscov
lopinavirritonavir
plu
interferonbeta
treatment
reduc
level
viru
replic
compar
vehicl
control
dpi
remdesivir
treatment
reduc
viral
titer
log
rel
vehicl
control
find
support
potenti
clinic
develop
remdesivir
merscov
antivir
novel
nonfus
replic
inhibitor
rsv
high
barrier
resist
kai
lin
enanta
pharmaceut
inc
watertown
usa
approv
vaccin
specif
antivir
therapi
current
exist
rsv
replic
inhibitor
develop
rsv
potent
vitro
activ
rsv
b
laboratori
strain
clinic
isol
ec
nm
potent
previous
known
viral
nucleoprotein
inhibitor
african
green
monkey
infect
rsv
vehicl
control
arm
robust
viral
replic
peak
day
treat
anim
minim
viral
replic
effect
viral
load
reduct
rsv
fusion
polymeras
inhibitor
rapidli
select
viral
popul
reduct
suscept
studi
evalu
barrier
develop
resist
rsva
long
rsvb
washington
strain
serial
passag
presenc
increas
concentr
rsv
resist
could
forc
stepwis
increas
concentr
develop
resist
associ
decreas
fit
potent
mutat
n
protein
caus
decreas
sensit
also
result
lower
viral
titer
phase
studi
recent
complet
report
intern
respiratori
syncyti
viru
symposium
overal
demonstr
safeti
concern
phase
studi
rsv
human
control
infect
model
ongo
time
meet
replic
fit
season
influenza
virus
display
decreas
suscept
polymeras
inhibitor
baloxavir
larisa
gubareva
cdc
atlanta
ga
usa
clinic
trial
baloxavir
treatmentemerg
resist
detect
adult
children
typic
occur
day
later
amino
acid
substitut
conserv
residu
polymeras
acid
pa
protein
mf
commonli
report
chang
influenza
virus
substitut
associ
fold
decreas
baloxavir
suscept
caus
fold
decreas
suscept
chang
confer
fold
decreas
baloxavir
suscept
influenza
b
virus
substitut
report
impair
vitro
replic
capac
influenza
virus
analysi
pa
sequenc
influenza
b
virus
collect
us
season
reveal
amino
acid
substitut
two
virus
two
virus
one
viru
confer
reduc
suscept
baloxavir
gubareva
et
al
studi
report
replic
fit
virus
contain
substitut
pa
protein
replic
kinet
counterpart
wild
type
lack
pa
substitut
determin
mdck
cell
titer
viru
wild
type
similar
convers
titer
viru
log
lower
compar
wild
type
hpi
vivo
replic
fit
viru
evalu
use
ferret
model
ferret
shed
virus
wild
type
consecut
day
nasal
wash
titer
log
lower
dpi
anim
revers
methionin
isoleucin
residu
pa
protein
detect
time
point
pyrosequenc
analysi
get
addit
insight
replic
capac
wild
type
vs
viru
competit
growth
experi
carri
ferret
coinocul
virus
ratio
total
pfu
pyrosequenc
analysi
viru
popul
nasal
wash
collect
period
reveal
increment
reduct
proport
viru
popul
conclus
pa
substitut
decreas
suscept
baloxavir
occur
rare
natur
set
without
baloxavir
treatment
pa
substitut
result
modestli
diminish
viral
replic
capac
insight
fluivig
random
placebo
control
trial
influenza
immunoglobulin
treatment
adult
hospit
influenza
richard
davey
niaidnih
bethesda
md
usa
year
anecdot
report
small
studi
give
convalesc
sera
plasma
blood
individu
recov
influenza
patient
sever
influenza
metaanalysi
report
influenza
pandem
conclud
earli
administr
convalesc
blood
product
reduc
absolut
risk
death
pneumonia
luke
et
al
random
control
trial
conduct
shortli
emerg
influenza
random
thirtyf
particip
receiv
high
titer
antiinfluenza
immun
immunoglobulin
ivig
nonimmun
prepandem
igiv
hung
et
al
receiv
immun
igiv
die
compar
receiv
standard
igiv
p
signific
though
benefit
report
post
hoc
analysi
particip
receiv
treatment
within
day
symptom
onset
fluivig
intern
multicent
doubleblind
placebocontrol
trial
enrol
adult
hospit
laboratori
confirm
influenza
news
elig
particip
random
receiv
either
singl
infus
antiinfluenza
high
titer
ivig
salin
placebo
particip
receiv
standard
nai
treatment
outcom
measur
ordin
scale
clinic
statu
day
favor
clinic
outcom
day
confid
interv
ci
p
or
influenza
b
ci
ci
respect
given
background
nai
treatment
high
titer
immun
ivig
provid
clinic
virolog
evid
favor
treatment
effect
overal
studi
cohort
appear
clinic
virolog
benefit
ivig
treatment
hospit
patient
influenza
b
infect
studi
cohort
find
warrant
investig
hightit
versu
lowtit
antiinfluenza
immun
plasma
treatment
sever
influenza
john
beigel
niaid
bethesda
md
usa
prior
studi
use
polyclon
plasma
treatment
sever
influenza
encourag
studi
howev
limit
significantli
limit
interpret
previous
note
metaanalysi
report
influenza
pandem
conclud
earli
administr
convalesc
blood
product
reduc
absolut
risk
death
pneumonia
luke
et
al
cohort
studi
conduct
evalu
use
convalesc
plasma
sever
influenza
infect
demonstr
decreas
mortal
p
hung
et
al
control
mortal
significantli
higher
expect
severityofil
prior
random
phase
studi
sever
influenza
b
demonstr
resolut
hypoxia
tachypnea
day
receiv
plasma
vs
standard
care
arm
p
beigel
et
al
studi
howev
differ
baselin
characterist
studi
group
asymmetr
loss
follow
two
studi
group
possibl
due
unblind
studi
design
studi
random
doubleblind
control
phase
trial
compar
hightit
antiinfluenza
plasma
hai
antibodi
titer
low
titer
plasma
hai
hospit
children
adult
sever
influenza
particip
enrol
icu
nonicu
patient
requir
oxygen
studi
termin
juli
independ
efficaci
analysi
reveal
low
condit
power
show
effect
hightit
plasma
even
full
accrual
achiev
proport
odd
ratio
improv
clinic
statu
ordin
scale
day
ci
p
despit
encourag
result
prior
studi
studi
insight
ivig
studi
suggest
polyclon
antibodi
therapi
may
significantli
improv
outcom
sever
influenza
examin
clinic
data
potenti
adjunct
therapi
influenza
nelson
lee
univers
alberta
edmonton
canada
meet
close
review
prior
work
adjunct
therapi
influenza
previous
note
high
mortal
rate
emerg
diseas
novel
coronaviru
infecti
mer
sar
novel
avian
influenza
strain
influenza
rais
question
possibl
role
proinflammatori
respons
pathogenesi
prior
studi
demonstr
cytokin
hyperactiv
associ
uncontrol
viral
replic
sustain
inflammatori
state
correl
diseas
progress
lead
respiratori
failur
ard
therapeut
target
pathogen
alon
thu
far
larg
unsuccess
revers
process
current
immunomodulatori
agent
conclus
proven
benefit
sever
influenza
corticosteroid
associ
increas
risk
superinfect
prolong
viral
replic
increas
risk
death
use
rodrigo
et
al
adjunct
therapi
data
less
clear
area
adjunct
therapi
support
data
may
worth
studi
review
combin
oseltamivir
azithromycin
shown
downregul
proinflammatori
cytokin
without
impair
viral
clearanc
one
small
rct
tripl
combin
oseltamivir
clarithromycin
naproxen
demonstr
reduc
advers
outcom
anoth
studi
hung
et
al
find
though
intrigu
confirm
sirolimu
use
appar
benefit
critic
ill
influenza
patient
context
rct
wang
et
al
confirmatori
studi
approach
without
concomit
corticosteroid
therapi
explor
efficaci
agent
potenti
immunomodul
effect
includ
nacetylcystein
nac
statin
nitazoxanid
ntz
ifn
peroxisom
proliferatoractiv
receptor
ppar
agonist
cyclooxygenas
cox
inhibitor
recombin
angiotensinconvert
enzym
diltiazem
herbal
medicin
support
preclin
clinic
data
need
studi
intens
prefer
rct
isirvavg
confer
opportun
investig
academia
industri
govern
present
hear
updat
preclin
clinic
effort
antivir
vaccin
influenza
rsv
merscov
respiratori
virus
confer
report
attempt
summar
main
find
present
given
meet
anticip
project
either
publish
applic
cite
manuscript
publish
peer
review
journal
reader
encourag
read
primari
literatur
topic
detail
studi
topic
present
dr
sim
declar
gilead
scienc
award
grant
univers
north
carolina
comparison
lopinavir
ritonavir
interferon
beta
treatment
treatment
remdesivir
author
noth
declar
none
content
public
necessarili
reflect
view
polici
us
depart
health
human
servic
mention
trade
name
commerci
product
organ
impli
endors
us
govern
